<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Zolmitriptan for acute migraine attacks in adults - Bird, S - 2014 | Cochrane Library</title> <meta content="Zolmitriptan for acute migraine attacks in adults - Bird, S - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008616.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Zolmitriptan for acute migraine attacks in adults - Bird, S - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008616.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008616.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Zolmitriptan for acute migraine attacks in adults" name="citation_title"/> <meta content="Sarah Bird" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="sheena.derry@retired.ox.ac.uk" name="citation_author_email"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD008616.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/05/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008616.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008616.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008616.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Pain [*drug therapy]; Administration, Oral; Migraine Disorders [*drug therapy]; Oxazolidinones [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Serotonin 5‐HT1 Receptor Agonists [adverse effects, *therapeutic use]; Time Factors; Tryptamines [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008616.pub2&amp;doi=10.1002/14651858.CD008616.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008616\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008616\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008616.pub2",title:"Zolmitriptan for acute migraine attacks in adults",firstPublishedDate:"May 21, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008616.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008616.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008616.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008616.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008616.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008616.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008616.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008616.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008616.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008616.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4379 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008616.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/appendices#CD008616-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/table_n/CD008616StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/table_n/CD008616StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Zolmitriptan for acute migraine attacks in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/information#CD008616-cr-0002">Sarah Bird</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/information#CD008616-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008616.pub2/information#CD008616-cr-0004">R Andrew Moore</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/information/en#CD008616-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 May 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008616.pub2">https://doi.org/10.1002/14651858.CD008616.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008616-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008616-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008616-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008616-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008616-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008616-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008616-abs-0001" lang="en"> <section id="CD008616-sec-0001"> <h3 class="title" id="CD008616-sec-0001">Background</h3> <p>Migraine is a common, disabling condition and a burden for the individual, health services, and society. Zolmitriptan is an abortive medication for migraine attacks, belonging to the triptan family. These medicines work in a different way to analgesics such as paracetamol and ibuprofen. </p> </section> <section id="CD008616-sec-0002"> <h3 class="title" id="CD008616-sec-0002">Objectives</h3> <p>To determine the efficacy and tolerability of zolmitriptan compared to placebo and other active interventions in the treatment of acute migraine attacks in adults. </p> </section> <section id="CD008616-sec-0003"> <h3 class="title" id="CD008616-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i>, MEDLINE, EMBASE, and the Oxford Pain Relief Database, together with three online databases (<a href="http://www.astrazenecaclinicaltrials.com" target="_blank">www.astrazenecaclinicaltrials.com</a>, <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>, and <a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>) for studies to 12 March 2014. We also searched the reference lists of included studies and relevant reviews. </p> </section> <section id="CD008616-sec-0004"> <h3 class="title" id="CD008616-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind, placebo‐ or active‐controlled studies, with at least 10 participants per treatment arm, using zolmitriptan to treat a migraine headache episode. </p> </section> <section id="CD008616-sec-0005"> <h3 class="title" id="CD008616-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. We used numbers of participants achieving each outcome to calculate risk ratios and numbers needed to treat for an additional beneficial effect (NNT) or harmful effect (NNH) compared with placebo or a different active treatment. </p> </section> <section id="CD008616-sec-0006"> <h3 class="title" id="CD008616-sec-0006">Main results</h3> <p>Twenty‐five studies (20,162 participants) compared zolmitriptan with placebo or an active comparator. The evidence from placebo‐controlled studies was of high quality for all outcomes except 24 hour outcomes and serious adverse events where only limited data were available. The majority of included studies were at a low risk of performance, detection and attrition biases, but did not adequately describe methods of randomisation and concealment. </p> <p>Most of the data were for the 2.5 mg and 5 mg doses compared with placebo, for treatment of moderate to severe pain. For all efficacy outcomes, zolmitriptan surpassed placebo. For oral zolmitriptan 2.5 mg versus placebo, the NNTs were 5.0, 3.2, 7.7, and 4.1 for pain‐free at two hours, headache relief at two hours, sustained pain‐free during the 24 hours postdose, and sustained headache relief during the 24 hours postdose, respectively. Results for the oral 5 mg dose were similar to the 2.5 mg dose, while zolmitriptan 10 mg was significantly more effective than 5 mg for pain‐free and headache relief at two hours. For headache relief at one and two hours and sustained headache relief during the 24 hours postdose, but not pain‐free at two hours, zolmitriptan 5 mg nasal spray was significantly more effective than the 5 mg oral tablet. </p> <p>For the most part, adverse events were transient and mild and were more common with zolmitriptan than placebo, with a clear dose response relationship (1 mg to 10 mg). </p> <p>High quality evidence from two studies showed that oral zolmitriptan 2.5 mg and 5 mg provided headache relief at two hours to the same proportion of people as oral sumatriptan 50 mg (66%, 67%, and 68% respectively), although not necessarily the same individuals. There was no significant difference in numbers experiencing adverse events. Single studies reported on other active treatment comparisons but are not described further because of the small amount of data. </p> </section> <section id="CD008616-sec-0007"> <h3 class="title" id="CD008616-sec-0007">Authors' conclusions</h3> <p>Zolmitriptan is effective as an abortive treatment for migraine attacks for some people, but is associated with increased adverse events compared to placebo. Zolmitriptan 2.5 mg and 5 mg benefited the same proportion of people as sumatriptan 50 mg, although not necessarily the same individuals, for headache relief at two hours. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008616-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008616-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008616-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008616-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008616-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008616-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008616-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008616-abs-0003" lang="en"> <h3>Zolmitriptan for acute migraine attacks in adults</h3> <p>Migraine is a complex condition with a wide variety of symptoms. It affects about 1 person in 8, mainly women aged 30 to 50 years. For many people, the main feature is a painful, and often disabling, headache. Other symptoms include feeling sick, vomiting, disturbed vision, and sensitivity to light, sound, and smells. </p> <p>Zolmitriptan is one of the triptan family of drugs. It is used to treat migraine attacks when they occur, not to prevent attacks occurring. It is available as an oral tablet to swallow whole, an oral tablet to dissolve in the mouth, and a nasal spray. This review looked at 25 studies that involved over 20,000 participants reporting the effects of zolmitriptan on migraine attacks. Most information was for tablets taken by mouth. Overall methodological quality of the included studies was good, and treatment group sizes were large enough to avoid major bias. There were inconsistencies in the way use of rescue medication and adverse events were reported. </p> <p>A single oral dose of zolmitriptan relieved migraine headache pain in some people. Several different pain outcomes were reported. </p> <p>One outcome was pain reduced from moderate or severe to no pain at all two hours after taking treatment. An oral zolmitriptan 2.5 mg tablet delivered this outcome to about 3 in 10 people (30%), compared with about 1 in 10 (10%) taking placebo. </p> <p>Another outcome was pain reduced from moderate or severe to no worse than mild pain two hours after taking treatment (called headache relief). An oral zolmitriptan 2.5 mg tablet delivered this outcome to about 6 in 10 people (61%), compared with 3 in 10 (29%) taking placebo. </p> <p>Slightly better results were obtained with higher doses of 5 mg or 10 mg oral tablets, but the 10 mg dose was associated with more adverse events, most of which were of short duration and mild or moderate in severity. Results for the 5 mg nasal spray were generally similar to those for the oral tablet, but it was significantly better than the tablet at 1 hour. </p> <p>People with migraine want treatment that eliminates the headache and any associated symptoms quickly (maximum two hours) and prevents it returning (within 24 hours). Results indicate that with the 5 mg dose only 14% of those treated were pain‐free at 2 hours with no headache recurrence within 24 hours. </p> <p>Oral zolmitriptan 2.5 mg and 5 mg provided headache relief at two hours to the same proportion of people (2 in 3) as oral sumatriptan 50 mg, with no difference in numbers experiencing adverse events. The individuals who respond to each drug may not be the same. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008616-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008616-sec-0093"></div> <h3 class="title" id="CD008616-sec-0094">Implications for practice</h3> <section id="CD008616-sec-0094"> <p>Zolmitriptan is an effective treatment for some people for the relief of headache pain and other symptoms associated with migraine, with single doses of 2.5 mg or more providing clinically useful levels of relief. People with migraine want treatment that eliminates the headache and any associated symptoms quickly (maximum two hours) and prevents it returning (within 24 hours). Results indicate that with the 5 mg dose only 14% of those treated will be pain‐free at two hours with no headache recurrence within 24 hours. </p> <p>There was no significant difference in efficacy between 2.5 mg and 5 mg doses for any outcome in these studies, but 10 mg was significantly better for the available outcomes of pain‐free and headache relief at two hours, and at 5 mg the nasal spray formulation was better than oral tablets for headache relief at one and two hours, but not pain‐free at two hours. The occurrence of adverse events was slightly greater in individuals taking zolmitriptan compared to those taking placebo, with significantly more adverse events with 10 mg than with 2.5 mg or 5 mg. Most events were described as mild and of short duration. </p> <p>Given that 2.5 mg and 5 mg produce the same effect, a 2.5 mg dose would be a sensible starting dose, with increase to 5 mg if there was inadequate response. The intranasal formulation provides more rapid relief of headache pain than oral tablets, but one in seven patients will experience taste disturbances. </p> </section> <h3 class="title" id="CD008616-sec-0095">Implications for research</h3> <section id="CD008616-sec-0095"> <p>Comparison of zolmitriptan with other active treatments in this review was severely compromised by the small number of available studies that compared zolmitriptan with the same active comparator at the same dose of comparator. Further large, good quality randomised controlled trials making direct comparisons of efficacy and harm between zolmitriptan and other triptans, common analgesics (aspirin, ibuprofen, paracetamol, diclofenac) and ergot derivatives now seem unlikely to be done. We do have large amounts of good quality data that compare different active therapies with placebo in identically designed and conducted studies, using the same outcomes over the same periods of time, and in similar participants; in these circumstances indirect comparison has been legitimised (<a href="./references#CD008616-bbs2-0076" title="SongF , AltmanDG , GlennyAM , DeeksJJ . Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta‐analyses. BMJ2003;326(7387):472. [DOI: 10.1136/bmj.326.7387.472] ">Song 2003</a>). It may also be possible to use existing study data for network meta‐analysis of very large amounts of high quality, consistently collected data in migraine headache. </p> <p>New studies should investigate the response to zolmitriptan in individuals who have not responded to other therapies, such as aspirin or sumatriptan, and why some people respond to one triptan but not another. </p> <p>More complete and consistent reporting of adverse events is necessary to properly assess their impact and make comparisons between different treatments. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008616-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008616-sec-0015"></div> <div class="table" id="CD008616-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral zolmitriptan 2.5 mg compared with placebo for migraine headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with migraine headache ‐ moderate or severe pain</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: oral zolmitriptan 2.5 mg</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> comparator</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> intervention</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>NNT or NNTH and/or<br/> relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies, attacks, events</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain‐free response at 2 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 5.0 (4.5 to 5.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 studies, 5223 attacks, 1157 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 2 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>610 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 3.2 (3.0 to 3.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 studies, 4567 attacks, 2184 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 1 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 6.0 (5.2 to 7.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 studies, 4123 attacks, 1273 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained pain‐free during the 24 h post dose</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 7.7 (5.9 to 11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies, 984 attacks, 145 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> <p>Downgraded due to small number of studies and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained headache relief during the 24 h post dose</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 4.1 (3.5 to 5.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 1457 attacks, 451 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least one AE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH 7.0 (6.1 to 8.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 studies, 5717 attacks, 1464 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher NNHs are better than lower NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious AE*</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.0 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.3 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>insufficient data to calculate</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,561 attacks, 30 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>*all doses &gt; 1 mg and all formulations combined</p> <p>Downgraded due to small number of events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AE:</b> adverse event;<b>CI:</b> Confidence interval; <b>NNT</b> : number needed to treat; <b>NNH</b>: number needed to harm </p> <p>Note: NNT or NNH is reported when an outcome is statistically different from placebo or comparator. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008616-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008616-sec-0016"></div> <section id="CD008616-sec-0017"> <h3 class="title" id="CD008616-sec-0017">Description of the condition</h3> <p>Migraine is a common, disabling headache disorder, ranked seventh highest among specific causes of disability globally (<a href="./references#CD008616-bbs2-0077" title="SteinerTJ , StovnerLJ , BirbeckGL . Migraine: the seventh disabler. Journal of Headache and Pain2013;14:1. [DOI: 10.1186/1129‐2377‐14‐1] ">Steiner 2013</a>), and with considerable social and economic impact (<a href="./references#CD008616-bbs2-0050" title="HazardE , MunakataJ , BigalME , RupnowMF , LiptonRB . The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health2009;12(1):55‐64. [DOI: 10.1111/j.1524‐4733.2008.00404.x] ">Hazard 2009</a>). Recent reviews found a one‐year prevalence of 15% globally (<a href="./references#CD008616-bbs2-0082" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163‐96. [DOI: 1016/S0140‐6736(12)61729‐2] ">Vos 2012</a>) and for adults in European countries (<a href="./references#CD008616-bbs2-0078" title="StovnerLJ , AndreeC . Prevalence of headache in Europe: a review for the Eurolight project. Journal of Headache and Pain2010;11(4):289‐99. [DOI: 10.1007/s10194‐010‐0217‐0] ">Stovner 2010</a>), 13% for all ages in the USA (<a href="./references#CD008616-bbs2-0081" title="VictorTW , HuX , CampbellJC , BuseDC , LiptonRB . Migraine prevalence by age and sex in the United States: a life‐span study. Cephalalgia2010;30(9):1065‐72. ">Victor 2010</a>), 21% in Russia (<a href="./references#CD008616-bbs2-0032" title="AyzenbergI , KatsaravaZ , SborowskiA , ChernyshM , OsipovaV , TabeevaG , et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia2012;32(5):373‐81. [DOI: 10.1177/0333102412438977] ">Ayzenberg 2012</a>), and 9% for adults in China (<a href="./references#CD008616-bbs2-0083" title="YuS , LiuR , ZhaoG , YangX , QiaoX , FengJ , et al. The prevalence and burden of primary headaches in China: a population‐based door‐to‐door survey. Headache2012;52(4):582‐91. [DOI: 10.1111/j.1526‐4610.2011.02061.x] ">Yu 2012</a>). Migraine is more prevalent in women than in men (by a factor of two to three), and in the age range 30 to 50 years. </p> <p>The International Headache Society (IHS) classifies two major subtypes (<a href="./references#CD008616-bbs2-0055" title="Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629‐808. [DOI: 10.1177/0333102413485658] ">IHS 2013</a>). Migraine without aura is the most common subtype. It is characterised by attacks lasting 4 to 72 hours that are typically of moderate to severe pain intensity, unilateral, pulsating, aggravated by normal physical activity, and associated with nausea with or without photophobia and phonophobia. Migraine with aura is characterised by reversible focal neurological symptoms that develop over a period of at least 5 minutes and last for less than 60 minutes, followed by headache with the features of migraine without aura. In some cases, the headache may lack migrainous features or be absent altogether (<a href="./references#CD008616-bbs2-0055" title="Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629‐808. [DOI: 10.1177/0333102413485658] ">IHS 2013</a>). </p> <p>A large prevalence study in the USA found that over half of migraineurs had severe impairment or required bed rest during attacks. Despite this high level of disability and a strong desire for successful treatment, only a proportion of people with migraine seek professional advice for the treatment of attacks. The majority were not taking any preventive medication, although one‐third met guideline criteria for being offered or considering it. Nearly all (98%) migraineurs used acute treatments for attacks, with 49% using over‐the‐counter (OTC) medication only, 20% using prescription medication, and 29% using both. OTC medications included aspirin, other non‐steroidal anti‐inflammatory drugs (NSAIDs), paracetamol (acetaminophen), and paracetamol plus caffeine (<a href="./references#CD008616-bbs2-0033" title="BigalME , SerranoD , ReedM , LiptonRB . Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology2008;71(8):559‐66. [DOI: 10.1212/01.wnl.0000323925.29520.e7] ">Bigal 2008</a>; <a href="./references#CD008616-bbs2-0045" title="DiamondS , BigalME , SilbersteinS , LoderE , ReedM , LiptonRB . Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache2007;47(3):355‐63. [DOI: 10.1111/j.1526‐4610.2006.00631.x] ">Diamond 2007</a>; <a href="./references#CD008616-bbs2-0064" title="LiptonRB , BigalME , DiamondM , FreitagF , ReedML , AMPP Advisory Group, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology2007;68(5):343‐9. ">Lipton 2007</a>). Similar findings have been reported from other large studies in France and Germany (<a href="./references#CD008616-bbs2-0065" title="LucasC , GéraudG , ValadeD , ChautardMH , Lantéri‐MinetM . Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population‐based survey. Headache2006;46(5):715‐25. [DOI: 10.1111/j.1526‐4610.2006.00430.x] ">Lucas 2006</a>; <a href="./references#CD008616-bbs2-0074" title="RadtkeA , NeuhauserH . Prevalence and burden of headache and migraine in Germany. Headache2009;49(1):79‐89. [DOI: 10.1111/j.1526‐4610.2008.01263.x] ">Radtke 2009</a>). </p> <p>The significant impact of migraine with regard to pain, functional health, and well‐being is well documented (<a href="./references#CD008616-bbs2-0036" title="BuseD , ManackA , SerranoD , ReedM , VaronS , TurkelC , et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache2012;52(1):3‐17. [DOI: 10.1111/j.1526‐4610.2011.02046.x] ">Buse 2011</a>; <a href="./references#CD008616-bbs2-0061" title="LeonardiM , SteinerTJ , ScherAT , LiptonRB . The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). Journal of Headache and Pain2005;6(6):429‐40. [DOI: 10.1007/s10194‐005‐0252‐4] ">Leonardi 2005</a>); it is ranked in the top 10 disorders for global years lived with disability (<a href="./references#CD008616-bbs2-0082" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163‐96. [DOI: 1016/S0140‐6736(12)61729‐2] ">Vos 2012</a>). A cross‐sectional survey of eight European Union (EU) countries (representing 55% of the adult population) has estimated an annual direct and indirect cost of migraine per person of EUR 1222, and a total annual cost for the EU of EUR 111 billion for adults aged 18 to 65 years (<a href="./references#CD008616-bbs2-0062" title="LindeM , GustavssonA , StovnerLJ , SteinerTJ , BarréJ , KatsaravaZ , et al. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology2012;19(5):703‐11. [DOI: 10.1111/j.1468‐1331.2011.03612.x] ">Linde 2012</a>). Costs vary between countries, probably due to differences in available therapies and the way they are delivered and structural differences in healthcare systems (<a href="./references#CD008616-bbs2-0034" title="BloudekLM , StokesM , BuseDC , WilcoxTK , LiptonRB , GoadsbyPJ , et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). Journal of Headache and Pain2012;13(5):361‐78. [DOI: 10.1007/s10194‐012‐0460‐7] ">Bloudek 2012</a>). In the USA, the mean annual direct cost per person has been estimated at USD 1757 for episodic migraine and USD 7750 for chronic migraine (<a href="./references#CD008616-bbs2-0070" title="MunakataJ , HazardE , SerranoD , KlingmanD , RupnowMF , TierceJ , et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache2009;49(4):498‐508. [DOI: 10.1111/j.1526‐4610.2009.01369.x] ">Munakata 2009</a>). Whatever the exact direct and indirect costs are for each country, it is clear that they are substantial. Successful treatment of acute migraine attacks not only benefits patients by reducing their disability and improving health‐related quality of life, but also has the potential to reduce the need for healthcare resources and increase economic productivity. </p> </section> <section id="CD008616-sec-0018"> <h3 class="title" id="CD008616-sec-0018">Description of the intervention</h3> <p>The symptomatic treatment of migraine advanced significantly with the development of the triptan class of drugs, of which sumatriptan was the first, in 1991. Zolmitriptan (trade names include Zomig, Zomigon, Zomigoro, AscoTop) is a second‐generation triptan, available as a standard tablet to be swallowed whole (2.5 mg), an oral disintegrating tablet (also called a 'melt'; 2.5 mg and 5 mg), and a nasal spray (5 mg). The disintegrating tablet contains aspartame, which can cause headache in some individuals and should be avoided by them. It dissolves rapidly in the mouth and can be swallowed without the need for fluid intake. It confers convenience, and may also provide faster onset of action if it dissolves sufficiently quickly to allow substantial uptake through the buccal mucosa. The nasal spray provides a route of administration that avoids oral ingestion altogether, which may be preferable for those who experience nausea and vomiting with migraine attacks. It also partly avoids the problem of slow absorption due to gastric stasis, which is commonly experienced. Up to 30% of the absorbed drug is taken up across the nasal mucosa, mostly immediately after dosing, and this may also lead to a faster onset of action. </p> <p>The 'recommended' dose in the United Kingdom (UK) is 2.5 mg, with an optional second 2.5 mg dose for recurrence, and subsequent 5 mg for the next attack if 2.5 mg provides inadequate relief (<a href="./references#CD008616-bbs2-0035" title="Zolmitriptan. British National Formulary2013; Vol. March:Available at http://www.medicinescomplete.com/mc/bnf/current/PHP2859‐zolmitriptan.htm. ">BNF 2013</a>). The maximum dose is 10 mg in 24 hours. In England in 2011 there were 300,000 prescriptions for zolmitriptan in primary care, almost two‐thirds of which were for the standard 2.5 mg tablet (<a href="./references#CD008616-bbs2-0072" title="Anonymous . Prescription cost analysis, England 2011. The NHS Information Centre, Prescribing Support Unit2012. [ISBN: 978‐1‐84636‐685‐7] ">PCA 2012</a>). In the USA recommended doses are lower (1.25 or 2.5 mg) but as in the UK, the maximum dose in 24 hours is 10 mg. </p> <p>In order to establish whether zolmitriptan is an effective treatment for migraine at a specified dose in acute migraine attacks, it is necessary to study its effects in circumstances that permit detection of pain relief. Such studies are carried out in individuals with established pain of moderate to severe intensity, using single doses of the interventions. Participants who experience an inadequate response with either placebo or active treatment are permitted to use rescue medication, and the intervention is considered to have failed in those individuals. In clinical practice, however, individuals would not normally wait until pain is of at least moderate severity, and may take a second dose of medication if the first dose does not provide adequate relief. Once efficacy is established in studies using single doses in established pain, further studies may investigate different treatment strategies and patient preferences. These are likely to include treating the migraine attack early while pain is mild, and using a low dose initially, with a second dose if the response is inadequate. </p> </section> <section id="CD008616-sec-0019"> <h3 class="title" id="CD008616-sec-0019">How the intervention might work</h3> <p>Zolmitriptan is a 5‐hydroxytryptamine 1 (5‐HT<sub>1)</sub> agonist, mainly targeting the 5‐HT (serotonin) 1B and 1D receptors. It has three putative mechanisms of therapeutic action (<a href="./references#CD008616-bbs2-0047" title="FerrariMD , GoadsbyPJ , RoonKI , LiptonRB . Triptans (serotonin, 5‐HT1B/1D agonists) in migraine: detailed results and methods of a meta‐analysis of 53 trials. Cephalalgia2002;22(8):633‐58. [DOI: 10.1046/j.1468‐2982.2002.00404.x] ">Ferrari 2002</a>; <a href="./references#CD008616-bbs2-0049" title="GoadsbyPJ . Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends in Molecular Medicine2007;13(1):39‐44. [DOI: 10.1016/j.molmed.2006.11.005] ">Goadsby 2007a</a>): </p> <p> <ul id="CD008616-list-0001"> <li> <p>vasoconstriction of dilated meningeal blood vessels;</p> </li> <li> <p>inhibition of the release of vasoactive neuropeptides from perivascular trigeminal sensory neurons; </p> </li> <li> <p>reduction of pain signal transmission in the trigeminal dorsal horn.</p> </li> </ul> </p> <p>It is used for acute treatment, having no efficacy in preventing future attacks.</p> </section> <section id="CD008616-sec-0020"> <h3 class="title" id="CD008616-sec-0020">Why it is important to do this review</h3> <p>There are a number of studies investigating the efficacy and tolerability of zolmitriptan for the treatment of acute migraine attacks, but no Cochrane review of these studies. Several treatment options are available to treat acute migraine headaches, including sumatriptan (<a href="./references#CD008616-bbs2-0040" title="DerryCJ , DerryS , MooreRA . Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD008615.pub2] ">Derry 2012a</a>; <a href="./references#CD008616-bbs2-0041" title="DerryCJ , DerryS , MooreRA . Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009665] ">Derry 2012b</a>; <a href="./references#CD008616-bbs2-0042" title="DerryCJ , DerryS , MooreRA . Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009663] ">Derry 2012c</a>; <a href="./references#CD008616-bbs2-0043" title="DerryCJ , DerryS , MooreRA . Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009664] ">Derry 2012d</a>) and common OTC analgesics such as aspirin (<a href="./references#CD008616-bbs2-0059" title="KirthiV , DerryS , MooreRA , McQuayHJ . Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008041.pub3] ">Kirthi 2013</a>), ibuprofen (<a href="./references#CD008616-bbs2-0073" title="RabbieR , DerryS , MooreRA , McQuayHJ . Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008039.pub3] ">Rabbie 2013</a>), and paracetamol (<a href="./references#CD008616-bbs2-0044" title="DerryS , MooreRA , McQuayHJ . Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008040.pub3] ">Derry 2013</a>). This is one of a series of reviews planned for acute treatments for migraine headaches. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008616-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008616-sec-0021"></div> <p>To determine the efficacy and tolerability of zolmitriptan compared to placebo and other active interventions in the treatment of acute migraine headaches in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008616-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008616-sec-0022"></div> <section id="CD008616-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008616-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included randomised, double‐blind, placebo‐ or active‐controlled studies using zolmitriptan to treat a migraine headache episode. Studies had to have a minimum of 10 participants per treatment arm and report dichotomous data for at least one of the outcomes specified below. We accepted studies reporting treatment of consecutive headache episodes if outcomes for the first, or each, episode were reported separately; we used first‐attack data preferentially. We accepted cross‐over studies if there was adequate (≥ 48 hours) washout between treatments. </p> </section> <section id="CD008616-sec-0025"> <h4 class="title">Types of participants</h4> <p>Studies enrolled adults (at least 18 years of age) with episodic migraine. We used the definition of migraine specified by the International Headache Society (IHS) (<a href="./references#CD008616-bbs2-0052" title="Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia1988;8(Suppl 7):1‐96. ">IHS 1988</a>; <a href="./references#CD008616-bbs2-0054" title="Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia2004;24(Suppl 1):1‐160. ">IHS 2004</a>; <a href="./references#CD008616-bbs2-0055" title="Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629‐808. [DOI: 10.1177/0333102413485658] ">IHS 2013</a>) and excluded studies evaluating treatments for chronic migraine. There were no other restrictions on migraine frequency, duration, or type (with or without aura). We accepted studies that included participants taking stable prophylactic therapy to reduce the frequency of migraine attacks. If reported, details on any prophylactic therapy prescribed or allowed are provided in the <a href="./references#CD008616-sec-0129" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD008616-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We included studies that used a single dose of zolmitriptan to treat a migraine headache episode when pain was of moderate to severe intensity, or investigated different dosing strategies or timing of the first dose in relation to headache intensity, or both. There were no restrictions on dose or route of administration, provided the medication was self‐administered. </p> <p>A placebo comparator is essential to demonstrate that zolmitriptan is effective in this condition. We considered active‐controlled trials without a placebo as secondary evidence. We excluded studies designed to demonstrate prophylactic efficacy in reducing the number or frequency of migraine attacks. </p> </section> <section id="CD008616-sec-0027"> <h4 class="title">Types of outcome measures</h4> <p>In selecting the main outcome measures for this review, we considered scientific rigour, availability of data, and patient preferences. Patients with acute migraine headaches have rated complete pain relief, no headache recurrence, rapid onset of pain relief, and no side effects as the four most important outcomes (<a href="./references#CD008616-bbs2-0063" title="LiptonRB , StewartWF . Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache1999;39(Suppl 2):S20‐S26. ">Lipton 1999</a>). </p> <p>In view of these patient preferences, and in line with the guidelines for controlled trials of drugs in migraine issued by the IHS (<a href="./references#CD008616-bbs2-0053" title="International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia2000;20(9):765‐86. ">IHS 2000</a>), we considered the following main outcomes. </p> <section id="CD008616-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008616-list-0002"> <li> <p>Pain‐free at two hours, without the use of rescue medication.</p> </li> <li> <p>Reduction in headache pain ('headache relief') at two hours (pain reduced from moderate or severe to none or mild without the use of rescue medication). </p> </li> </ul> </p> <p>We also collected data for pain‐free and headache relief outcomes at one hour if reported and relevant, for example, if a fast‐acting formulation of the intervention was tested. For the purposes of this review, we considered the nasal spray and oral disintegrating tablet formulations to be potentially fast‐acting. </p> </section> <section id="CD008616-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008616-list-0003"> <li> <p>Sustained pain‐free during the 24 hours postdose (pain‐free within two hours, with no use of rescue medication or recurrence of pain of any intensity within 24 hours). </p> </li> <li> <p>Sustained headache relief during the 24 hours postdose (headache relief at two hours, with no use of rescue medication or a second dose of study medication, or recurrence of moderate or severe pain within 24 hours). </p> </li> <li> <p>Adverse events: participants with any adverse event during the 24 hours postdose; serious adverse events; adverse events leading to withdrawal. </p> </li> </ul> </p> <section id="CD008616-sec-0030"> <h6 class="title">Other outcomes</h6> <p>We also collected data for other outcomes, including:</p> <p> <ul id="CD008616-list-0004"> <li> <p>use of rescue medication;</p> </li> <li> <p>relief of headache‐associated symptoms;</p> </li> <li> <p>relief of functional disability.</p> </li> </ul> </p> <p>Pain intensity or pain relief had to be measured by the participant (not the investigator or care giver). Pain measures accepted for the main efficacy outcomes were the following. </p> <p> <ul id="CD008616-list-0005"> <li> <p>Pain intensity: 4‐point categorical scale, with wording equivalent to none, mild, moderate and severe; or 100 mm VAS, where &lt; 30 mm was considered equivalent to mild or no pain and ≥ 30 mm equivalent to moderate or severe pain (<a href="./references#CD008616-bbs2-0038" title="CollinsSL , MooreRA , McQuayHJ . The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain1997;72(1‐2):95‐7. ">Collins 1997</a>). </p> </li> <li> <p>Pain relief: 5‐point categorical scale, with wording equivalent to none, a little, some, a lot, complete; or 100 mm VAS, where &lt; 30 mm was considered equivalent to none or a little, and ≥ 30 mm equivalent to some, a lot or complete. </p> </li> </ul> </p> <p>Definitions of important terms, including all measured outcomes, are provided in <a href="./appendices#CD008616-sec-0099">Appendix 1</a>. </p> </section> </section> </section> </section> <section id="CD008616-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008616-sec-0032"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD008616-list-0006"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL), <i>The Cochrane Library</i> (Issue 3 of 12, 2014). </p> </li> <li> <p>MEDLINE (via Ovid) (1990 to 12 March 2014).</p> </li> <li> <p>EMBASE (via Ovid) (1990 to 12 March 2014).</p> </li> <li> <p>Oxford Pain Relief Database, searched on 22 May 2013 (<a href="./references#CD008616-bbs2-0056" title="JadadAR , CarrollD , MooreA , McQuayH . Developing a database of published reports of randomised clinical trials in pain research. Pain1996;66(2‐3):239‐46. ">Jadad 1996a</a>). </p> </li> </ul> </p> <p>See <a href="./appendices#CD008616-sec-0100">Appendix 2</a>, <a href="./appendices#CD008616-sec-0101">Appendix 3</a>, and <a href="./appendices#CD008616-sec-0102">Appendix 4</a> for the search strategies for CENTRAL, MEDLINE (via Ovid), and EMBASE (via Ovid), respectively. </p> <p>Searches of MEDLINE and EMBASE started in 2009 because we were looking only for randomised controlled trials and these two databases are routinely searched and all controlled trials added to CENTRAL. This may not capture studies that have been published or indexed in the previous year, but searching back to 2009 provided a considerable overlap. We did not apply any language restrictions. </p> </section> <section id="CD008616-sec-0033"> <h4 class="title">Searching other resources</h4> <p>We searched for additional studies in reference lists of retrieved studies and review articles, and in three clinical trials databases (<a href="http://www.astrazenecaclinicaltrials.com" target="_blank">www.astrazenecaclinicaltrials.com</a>, <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>, and <a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>). AstraZeneca, the manufacturer of Zomig, provided a database search of publications relating to zolmitriptan in migraine; no mention of unpublished data was made. No studies, published or unpublished, were identified in the list they provided that were not identified by our searches. </p> </section> </section> <section id="CD008616-sec-0034"> <h3 class="title" id="CD008616-sec-0034">Data collection and analysis</h3> <section id="CD008616-sec-0035"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently carried out the searches and selected studies for inclusion. We viewed the titles and abstracts of all studies identified by the electronic searches on screen and excluded any that clearly did not satisfy the inclusion criteria. We read full copies of the remaining studies to identify those suitable for inclusion. Disagreements were settled by discussion with a third review author. </p> </section> <section id="CD008616-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from the included studies using a standard data extraction form. We settled disagreements by discussion with a third review author. One review author entered data into Review Manager 5 (<a href="./references#CD008616-bbs2-0075" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> </section> <section id="CD008616-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score (<a href="./references#CD008616-bbs2-0057" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJM , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. ">Jadad 1996b</a>) as the basis for inclusion, limiting inclusion to studies that were randomised and double‐blind as a minimum. The scores for each study are reported in the <a href="./references#CD008616-sec-0129" title="">Characteristics of included studies</a> table. </p> <p>Two review authors independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008616-bbs2-0051" title="HigginsJPT , GreenS (editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , AltmanDG , SterneJAC editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We assessed the following for each study. </p> <p> <ol id="CD008616-list-0007"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, eg random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (eg odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (eg telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (eg open list). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, eg identical tablets; matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved). We excluded studies that were not double‐blind. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (&lt; 10% of participants provided no data without acceptable reason, eg they were randomised but did not have a qualifying headache). We excluded studies with high data loss. </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (≥ 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm). </p> </li> </ol> </p> </section> <section id="CD008616-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratios (relative risk; RR) to establish statistical difference. Numbers needed to treat (NNT) and pooled percentages were used as absolute measures of benefit or harm. </p> <p>We used the following terms to describe adverse outcomes in terms of harm or prevention of harm: </p> <p> <ul id="CD008616-list-0008"> <li> <p>when significantly fewer adverse outcomes occurred with zolmitriptan than with control (placebo or active), we use the term the number needed to treat to prevent one event (NNTp). </p> </li> <li> <p>when significantly more adverse outcomes occurred with zolmitriptan compared with control (placebo or active), we use the term the number needed to harm or cause one event (NNH). </p> </li> </ul> </p> </section> <section id="CD008616-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>We accepted randomisation to the individual patient only. For analysis of studies with more than one treatment arm contributing to any one analysis (for example two formulations of the same dose of zolmitriptan in the same study with a single placebo group), we would split the placebo group equally between the two treatment arms so as not to double‐count placebo participants. </p> <p>Where participants treated more than one attack we used first attack data preferentially. When that was not reported we have used data from combined attacks and have considered how this might affect the results. </p> </section> <section id="CD008616-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>The most likely source of missing data was in cross‐over studies; we planned to use only the first‐period data where possible, but where that was not provided we treated the results as if they were parallel group results. Where there were substantial missing data in any study, we would comment on this and perform sensitivity analyses to investigate their effect. </p> <p>For all outcomes we carried out analyses, as far as possible, on a modified intention‐to‐treat (ITT) basis, that is, we included all participants who were randomised and received an intervention. Where sufficient information was reported, we re‐included missing data in the analyses we undertook. We planned to exclude data from outcomes where data from 10% or more of participants were missing with no acceptable reason provided or apparent. </p> </section> <section id="CD008616-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of response rates using L'Abbé plots, a visual method for assessing differences in the results of individual studies (<a href="./references#CD008616-bbs2-0060" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta‐analysis in clinical research. Annals of Internal Medicine1987;107(2):224‐33. ">L'Abbé 1987</a>). Where data could be pooled, we reported the I<sup>2</sup> statistic. </p> </section> <section id="CD008616-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias by examining the number of participants in trials with zero effect (relative risk of 1.0) needed for the point estimate of the NNT to increase beyond a clinically useful level (<a href="./references#CD008616-bbs2-0067" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). In this case, we specified a clinically useful level as a NNT of 8 or greater for pain‐free at two hours, and NNT of 6 or greater for headache relief at two hours. </p> </section> <section id="CD008616-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We analysed studies using a single dose of zolmitriptan in established pain of at least moderate intensity separately from studies in which the medication was taken before pain became well established, or in which a second dose of medication was permitted. </p> <p>We calculated effect sizes and combined data for analysis only for comparisons and outcomes where there were at least two studies and 200 participants (<a href="./references#CD008616-bbs2-0066" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. ">Moore 1998</a>). Relative risk (RR) of benefit ('relative benefit') or harm ('relative risk') was calculated with 95% confidence intervals (CIs) using a fixed‐effect model (<a href="./references#CD008616-bbs2-0069" title="MorrisJA , GardnerMJ . Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: GardnerMJ , AltmanDG editor(s). Statistics with confidence ‐ confidence intervals and statistical guidelines. London: British Medical Journal, 1995:50‐63. ">Morris 1995</a>). We calculated NNT, NNTp, and NNH with 95% CIs, where possible, using the pooled number of events by the method of Cook and Sackett (<a href="./references#CD008616-bbs2-0039" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ1995;310(6977):452‐4. ">Cook 1995</a>). We assumed a statistically significant difference from control when the 95% CI of the RR of benefit or harm did not include the number one. </p> <p>We used the z test (<a href="./references#CD008616-bbs2-0080" title="TramèrMR , ReynoldsDJM , MooreRA , McQuayHJ . Impact of covert duplicate results on meta‐analysis: a case study. BMJ1997;315(7109):635‐40. ">Tramer 1997</a>) to determine significant differences between NNT, NNTp, and NNH for different groups in subgroup and sensitivity analyses. </p> <p>We described data from comparisons and outcomes with only one study or fewer than 200 participants in the summary tables and text, where appropriate, for information and comparison, but we did not analyse these data quantitatively. </p> </section> <section id="CD008616-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Issues for potential subgroup analysis were dose, formulation, and route of administration.</p> </section> <section id="CD008616-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analysis for study quality (Oxford Quality Score of 2 versus 3 or more) and for migraine type (with aura versus without aura). A minimum of two studies and 200 participants had to be available for any sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008616-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008616-sec-0046"></div> <section id="CD008616-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD008616-sec-0048"> <h4 class="title">Results of the search</h4> <p>Searches of bibliographic databases identified over 800 potentially relevant reports, of which 34 were examined in detail after screening titles and abstracts. We included 25 studies in the review, two of which had published subgroup analyses in three additional reports, and another had a published post‐hoc analysis. We also identified, from the World Health Organization (WHO) international clinical trials registry platform, one additional study with 126 participants (<a href="./references#CD008616-bbs2-0030" title="Dr Avanti Biniwale (Principleinvestigator) . A Clinical Trial to evaluate efficacy and safety of zolmitriptan 5 mg nasal spray in acute treatment of migraine. http://ctri.nic.in (accessed 13 November 2013)2013. [CTRI/2009/091/000196] ">CTRI/2009/091/000196</a>). This study appears to satisfy the inclusion criteria, but has not been published, and the report does not provide sufficient data for us to include it in this review. The report claims that results "are similar to the published studies"; details are in the <a href="./references#CD008616-sec-0131" title="">Characteristics of studies awaiting classification</a> table. Three studies (four reports) were excluded (<a href="#CD008616-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008616-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD008616-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> </section> <section id="CD008616-sec-0049"> <h4 class="title">Included studies</h4> <p>Twenty‐five studies fulfilled the inclusion criteria for this review (<a href="./references#CD008616-bbs2-0001" title="AstraZeneca . A multicentre, randomised, double‐blind trial to compare the efficacy and safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and placebo in the acute treatment of adult patients with migraine. www.astrazenecaclinicaltrials.com2005. ">311CIL/0099 2000</a>; <a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>; <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0010" title="GeraudG , CompagnonA , RossiA , COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double‐blind, randomised, three‐attack study. European Neurology2002;47(2):88‐98. ">Geraud 2002</a>; <a href="./references#CD008616-bbs2-0011" title="AllaisG , AcutoG , CabarrocasX , EsbriR , BenedettoC , BussoneG . Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences2006;27 Suppl 2:S193‐7. [DOI: 10.1007/s10072‐006‐0600‐4] GoadsbyPJ , MassiouH , PascualJ , DienerHC , DahlöfCG , MateosV . Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurologica Scandinavica2007;115(1):34‐40. ">Goadsby 2007b</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a>; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a>; <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0020" title="SolomonGD , CadyRK , KlapperJA , EarlNL , SaperJR , RamadanNM . Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology1997;49(5):1219‐25. ">Solomon 1997</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>; <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>) with contributions from a total of 20,162 participants. </p> <p>The studies tested the following interventions.</p> <p> <ul id="CD008616-list-0009"> <li> <p>Zolmitriptan standard oral tablet versus placebo (<a href="./references#CD008616-bbs2-0001" title="AstraZeneca . A multicentre, randomised, double‐blind trial to compare the efficacy and safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and placebo in the acute treatment of adult patients with migraine. www.astrazenecaclinicaltrials.com2005. ">311CIL/0099 2000</a>; <a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a>; <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0020" title="SolomonGD , CadyRK , KlapperJA , EarlNL , SaperJR , RamadanNM . Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology1997;49(5):1219‐25. ">Solomon 1997</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>). </p> </li> <li> <p>Zolmitriptan oral disintegrating tablet versus placebo (<a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>). </p> </li> <li> <p>Zolmitriptan nasal spray versus placebo (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>). </p> </li> <li> <p>Zolmitriptan versus ketoprofen (<a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>). </p> </li> <li> <p>Zolmitriptan versus sumatriptan (<a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>). </p> </li> <li> <p>Zolmitriptan versus acetylsalicylic acid plus metoclopramide (<a href="./references#CD008616-bbs2-0010" title="GeraudG , CompagnonA , RossiA , COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double‐blind, randomised, three‐attack study. European Neurology2002;47(2):88‐98. ">Geraud 2002</a>). </p> </li> <li> <p>Zolmitriptan versus almotriptan (<a href="./references#CD008616-bbs2-0011" title="AllaisG , AcutoG , CabarrocasX , EsbriR , BenedettoC , BussoneG . Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences2006;27 Suppl 2:S193‐7. [DOI: 10.1007/s10072‐006‐0600‐4] GoadsbyPJ , MassiouH , PascualJ , DienerHC , DahlöfCG , MateosV . Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurologica Scandinavica2007;115(1):34‐40. ">Goadsby 2007b</a>). </p> </li> <li> <p>Zolmitriptan versus telcagepant (<a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>). </p> </li> <li> <p>Zolmitriptan versus rizatriptan (<a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>). </p> </li> <li> <p>Zolmitriptan versus eletriptan (<a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>). </p> </li> <li> <p>Zolmitriptan versus frovatriptan (<a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a>). </p> </li> <li> <p>Zolmitriptan versus naratriptan (<a href="./references#CD008616-bbs2-0001" title="AstraZeneca . A multicentre, randomised, double‐blind trial to compare the efficacy and safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and placebo in the acute treatment of adult patients with migraine. www.astrazenecaclinicaltrials.com2005. ">311CIL/0099 2000</a>). </p> </li> </ul> </p> <p>Participants included in all of the studies were diagnosed with migraine with or without aura in accordance with the IHS criteria (<a href="./references#CD008616-bbs2-0052" title="Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia1988;8(Suppl 7):1‐96. ">IHS 1988</a>; <a href="./references#CD008616-bbs2-0054" title="Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia2004;24(Suppl 1):1‐160. ">IHS 2004</a>), typically had a history of migraine for more than one year, and suffered from one to six migraine attacks per month, with slight variances. For the most part, the participants recruited into the studies were between 18 and 65 years of age, although <a href="./references#CD008616-bbs2-0011" title="AllaisG , AcutoG , CabarrocasX , EsbriR , BenedettoC , BussoneG . Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences2006;27 Suppl 2:S193‐7. [DOI: 10.1007/s10072‐006‐0600‐4] GoadsbyPJ , MassiouH , PascualJ , DienerHC , DahlöfCG , MateosV . Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurologica Scandinavica2007;115(1):34‐40. ">Goadsby 2007b</a> included participants aged 16 to 65 years and <a href="./references#CD008616-bbs2-0020" title="SolomonGD , CadyRK , KlapperJA , EarlNL , SaperJR , RamadanNM . Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology1997;49(5):1219‐25. ">Solomon 1997</a> and <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a> included participants aged 12 to 65 years. In addition, <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a> and <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a> were not explicit about the age range of those included, but the mean ages were 39 years and 40 years, respectively. Although this review is focused on zolmitriptan for acute migraine solely in adults, we included these studies because we felt that the number of individuals younger than 18 years was small, and because all were ≥ 12 years of age they were likely to require an adult dose. Stable prophylactic medications were allowed in most of the studies with the exception of <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>, in which patients were excluded if they had used prophylactic treatment in the month before the study. Almost all studies stated that study medication was not to be used within 24 hours of taking a triptan or an ergot derivative. All studies included both men and women, except the study concerning menstrual migraine (<a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>). The participants in <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a> were required to have a diagnosis of menstrual migraine (<a href="./references#CD008616-bbs2-0052" title="Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia1988;8(Suppl 7):1‐96. ">IHS 1988</a>), with migraine occurring within two days of the expected onset of menses to five days after onset, and with &gt; 75% of all menstrual periods associated with migraine attacks. </p> <p>Twenty‐two of the included studies had a parallel‐group design, and three had a cross‐over design, of which <a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a> and <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a> specified at least 48 hours between treated attacks, and <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a> did not report a minimum time, but had a 48‐hour outcome, implying that qualifying attacks had to be separated by at least that period. Most studies instructed participants to treat a single migraine attack with the study medication, though in five studies participants treated multiple attacks (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>). Only in <a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a> and <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a> could first‐attack data for certain criteria be extracted, and these data were used where possible. </p> <p>In all studies rescue medication was allowed if the headache persisted, typically two hours after study medication had been taken. In a number of studies a second dose of study medication was allowed, either if the headache persisted or if it recurred (<a href="./references#CD008616-bbs2-0001" title="AstraZeneca . A multicentre, randomised, double‐blind trial to compare the efficacy and safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and placebo in the acute treatment of adult patients with migraine. www.astrazenecaclinicaltrials.com2005. ">311CIL/0099 2000</a>; <a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>; <a href="./references#CD008616-bbs2-0010" title="GeraudG , CompagnonA , RossiA , COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double‐blind, randomised, three‐attack study. European Neurology2002;47(2):88‐98. ">Geraud 2002</a>; <a href="./references#CD008616-bbs2-0011" title="AllaisG , AcutoG , CabarrocasX , EsbriR , BenedettoC , BussoneG . Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences2006;27 Suppl 2:S193‐7. [DOI: 10.1007/s10072‐006‐0600‐4] GoadsbyPJ , MassiouH , PascualJ , DienerHC , DahlöfCG , MateosV . Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurologica Scandinavica2007;115(1):34‐40. ">Goadsby 2007b</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>; <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>). The administration of zolmitriptan was via an oral tablet (standard or disintegrating) or a nasal spray, with the majority of studies using the standard oral tablet formulation. </p> <p>In most studies the treated migraine attacks had to be of moderate or severe baseline intensity. <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a> did not state pain intensity in the methods, but reported results for reduction from at least moderate to no greater than mild; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a> treated any severity, but fewer than 10% were mild, and results were reported separately for attacks of moderate or severe baseline intensity; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a> treated 'as soon as possible', but reported some outcomes for attacks of moderate or severe baseline intensity; <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a> treated 'as soon as possible', reporting for mixed baseline pain intensities. Finally, <a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a> treated when pain intensity was mild. </p> <p>Some studies were inconsistent in the denominators reported, so that the population varied slightly in size for different outcomes or at different time points. Where this variance was not explained in the text, the denominators were changed to the intention‐to‐treat (ITT) number if this gave a more conservative estimate of the efficacy of the drug. </p> </section> <section id="CD008616-sec-0050"> <h4 class="title">Excluded studies</h4> <p>Five studies were excluded after reading the full report (Dodick 2011; <a href="./references#CD008616-bbs2-0026" title="DowsonAJ , CharlesworthBR , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Tolerability and consistency of effect of zolmitriptan nasal spray in a long‐term migraine treatment trial. CNS Drugs2003;17(11):839‐51. ">Dowson 2003</a>; <a href="./references#CD008616-bbs2-0027" title="LoderE , SilbersteinSD , Abu‐ShakraS , MuellerL , SmithT . Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel‐group, double‐blind, placebo‐controlled study. Headache2004;44(2):120‐30. ">Loder 2004</a>; <a href="./references#CD008616-bbs2-0028" title="MauskopA , FarkkilaM , Hering‐HanitR , RapoportA , WarnerJ . Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache. Current Medical Research and Opinion1999;15(4):282‐9. ">Mauskop 1999</a>; <a href="./references#CD008616-bbs2-0029" title="TepperSJ , DonnanGA , DowsonAJ , BomhofMA , ElkindA , MelocheJ , et al. A long‐term study to maximise migraine relief with zolmitriptan. Current Medical Research and Opinion1999;15(4):254‐71. ">Tepper 1999</a>). The reasons for exclusion are provided in the <a href="./references#CD008616-sec-0130" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD008616-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>The included studies were all randomised and double‐blind. The majority of the studies provided information about withdrawals and dropouts; <a href="./references#CD008616-bbs2-0011" title="AllaisG , AcutoG , CabarrocasX , EsbriR , BenedettoC , BussoneG . Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences2006;27 Suppl 2:S193‐7. [DOI: 10.1007/s10072‐006‐0600‐4] GoadsbyPJ , MassiouH , PascualJ , DienerHC , DahlöfCG , MateosV . Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurologica Scandinavica2007;115(1):34‐40. ">Goadsby 2007b</a>, <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>, and <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a> either made no statement about withdrawals or did not give an adequate explantation for differing denominators. The methodological quality of the trials was determined using the Oxford Quality Scale (<a href="./references#CD008616-bbs2-0056" title="JadadAR , CarrollD , MooreA , McQuayH . Developing a database of published reports of randomised clinical trials in pain research. Pain1996;66(2‐3):239‐46. ">Jadad 1996a</a>). Six studies (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0010" title="GeraudG , CompagnonA , RossiA , COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double‐blind, randomised, three‐attack study. European Neurology2002;47(2):88‐98. ">Geraud 2002</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>) scored 5/5, 11 studies (<a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>; <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a>; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>) scored 4/5, seven studies (<a href="./references#CD008616-bbs2-0001" title="AstraZeneca . A multicentre, randomised, double‐blind trial to compare the efficacy and safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and placebo in the acute treatment of adult patients with migraine. www.astrazenecaclinicaltrials.com2005. ">311CIL/0099 2000</a>; <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0011" title="AllaisG , AcutoG , CabarrocasX , EsbriR , BenedettoC , BussoneG . Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences2006;27 Suppl 2:S193‐7. [DOI: 10.1007/s10072‐006‐0600‐4] GoadsbyPJ , MassiouH , PascualJ , DienerHC , DahlöfCG , MateosV . Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurologica Scandinavica2007;115(1):34‐40. ">Goadsby 2007b</a>; <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0020" title="SolomonGD , CadyRK , KlapperJA , EarlNL , SaperJR , RamadanNM . Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology1997;49(5):1219‐25. ">Solomon 1997</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>) scored 3/5 and one study (<a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a>) scored 2/5. Points were lost mainly due to inadequate description of the method of randomisation or double blinding, and also due to lack of information about withdrawals and drop‐outs. Most studies were performed for registration or other purposes by pharmaceutical companies and would have had to satisfy very strict requirements to randomisation and allocation concealment, and effectiveness of double blinding, although these were not always fully reported in the published studies. Details are provided in the <a href="./references#CD008616-sec-0129" title="">Characteristics of included studies</a> table. </p> <p>In addition a risk of bias table was created which considered sequence generation, allocation concealment, blinding, incomplete outcome data, and study size (<a href="#CD008616-fig-0002">Figure 2</a>). Only one study (<a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>) was identified as being at high risk of bias, due to small size, although one other study (<a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>) had group sizes very close to the cut‐off point of 50. </p> <div class="figure" id="CD008616-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008616-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> </section> <section id="CD008616-sec-0052"> <h3 class="title" id="CD008616-sec-0052">Effects of interventions</h3> <p>See: <a href="./full#CD008616-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>All included studies used a four‐point categorical scale (none, mild, moderate, severe) for rating pain intensity. </p> <p>In the great majority of studies participants treated attacks when pain was of moderate to severe intensity, or the study reported efficacy results separately for attacks where the baseline pain was moderate to severe. There were sufficient data for at least the primary outcomes of pain‐free and headache relief at two hours for pooled analyses of zolmitriptan versus placebo at doses of 1 mg, 2.5 mg, 5 mg and 10 mg, when used to treat moderate to severe pain. There were insufficient data to allow pooled analysis from studies in which participants treated attacks when pain was mild, or that included mixed baseline intensities. Unless otherwise stated, results reported in this review are for attacks of moderate to severe baseline pain intensity. There were also insufficient data from studies that allowed second or third doses of medication for a single attack in order to allow analysis of these different dosing strategies. </p> <p>Analyses of other doses of zolmitriptan versus placebo and almost any dose of zolmitriptan versus an active comparator, for any outcome, were not possible because there were insufficient data; it was common for only one study to provide data. We have reported results where analyses were possible in the text and tables in this section, and details of all results in individual studies are available in <a href="./appendices#CD008616-sec-0103">Appendix 5</a> (efficacy) and <a href="./appendices#CD008616-sec-0104">Appendix 6</a> (adverse events and withdrawals). </p> <p>For all analysis graphs, studies have used oral tablets unless otherwise noted in the footnotes. </p> <p>See 'Summary of results A' for results of all efficacy outcomes.</p> <section id="CD008616-sec-0053"> <h4 class="title">Pain‐free at two hours</h4> <section id="CD008616-sec-0054"> <h5 class="title">Zolmitriptan 1 mg versus placebo</h5> <p>Four studies (1200 attacks) provided data comparing zolmitriptan 1 mg with placebo. Three studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>) and one a nasal spray formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>). </p> <p> <ul id="CD008616-list-0010"> <li> <p>The proportion of attacks pain‐free at two hours with zolmitriptan 1 mg was 22% (138/621; range 9% to 25%). </p> </li> <li> <p>The proportion of attacks pain‐free at two hours with placebo was 8.1% (47/579; range 5% to 14%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.7 (95% CI 2.0 to 3.7; <a href="./references#CD008616-fig-0007" title="">Analysis 1.1</a>); the NNT was 7.1 (5.5 to 9.9). </p> </li> <li> <p>For oral treatment alone, the relative benefit of treatment compared with placebo was 1.9 (1.1 to 3.3) and the NNT was 14 (7.4 to 170). </p> </li> </ul> </p> </section> <section id="CD008616-sec-0055"> <h5 class="title">Zolmitriptan 2.5 mg versus placebo</h5> <p>Eleven studies (5825 attacks) provided data comparing zolmitriptan 2.5 mg with placebo. Each of the 11 studies used an oral tablet (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a>; <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0020" title="SolomonGD , CadyRK , KlapperJA , EarlNL , SaperJR , RamadanNM . Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology1997;49(5):1219‐25. ">Solomon 1997</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>), with one of these studies also providing information on the use of a zolmitriptan 2.5 mg nasal spray (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>). </p> <p> <ul id="CD008616-list-0011"> <li> <p>The proportion of attacks pain‐free at two hours with zolmitriptan 2.5 mg was 30% (1030/3455; range 19% to 36%). </p> </li> <li> <p>The proportion of attacks pain‐free at two hours with placebo was 10% (243/2370; range 6% to 17%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 3.0 (2.6 to 3.5) (<a href="#CD008616-fig-0003">Figure 3</a>; <a href="./references#CD008616-fig-0012" title="">Analysis 2.1</a>); the NNT was 5.1 (4.7 to 5.7). </p> </li> <li> <p>For oral treatment alone, the relative benefit of treatment compared with placebo was 3.0 (2.6 to 3.5) and the NNT was 5.0 (4.5 to 5.6). </p> </li> </ul> </p> <div class="figure" id="CD008616-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Zolmitriptan 2.5 mg versus placebo, outcome: 2.1 Pain‐free at 2 h. Studies without footnotes use the standard oral tablet." data-id="CD008616-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Zolmitriptan 2.5 mg versus placebo, outcome: 2.1 Pain‐free at 2 h. Studies without footnotes use the standard oral tablet. </p> </div> </div> </div> <p>Zolmitriptan 2.5 mg was significantly better than 1 mg (z = 3.933, P = 0.0001). A L'Abbé plot shows the similarity in results between studies (<a href="#CD008616-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD008616-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="L'Abbé plot showing results for zolmitriptan 2.5 mg versus placebo for pain‐free at 2 hours. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence" data-id="CD008616-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>L'Abbé plot showing results for zolmitriptan 2.5 mg versus placebo for pain‐free at 2 hours. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence </p> </div> </div> </div> <p><a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a> compared zolmitriptan 2.5 mg with placebo to treat headache of mild intensity; 43% (59/138) of participants were pain‐free at two hours with zolmitriptan, while 18% (26/142) experienced this outcome with placebo. </p> </section> <section id="CD008616-sec-0056"> <h5 class="title">Zolmitriptan 5 mg versus placebo</h5> <p>Eleven studies (9372 attacks) provided data comparing zolmitriptan 5 mg with placebo. Eight studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>), whilst the other three studies used a nasal spray formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>). </p> <p> <ul id="CD008616-list-0012"> <li> <p>The proportion of attacks pain‐free at two hours with zolmitriptan 5 mg was 32% (1616/5024; range 14% to 39%). </p> </li> <li> <p>The proportion of attacks pain‐free at two hours with placebo was 11% (481/4348; range 2% to 14%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 3.0 (2.7 to 3.2; <a href="./references#CD008616-fig-0020" title="">Analysis 3.1</a>); the NNT was 4.7 (4.4 to 5.1). </p> </li> <li> <p>For oral treatment alone, the relative benefit of treatment compared to placebo was 3.2 (2.7 to 3.7) and the NNT was 4.8 (4.3 to 5.4), while for nasal spray alone, the relative benefit of treatment compared to placebo was 2.8 (2.5 to 3.2) and the NNT was 4.6 (4.2 to 5.2). </p> </li> </ul> </p> <p>There was no statistically significant difference between the two formulations for the outcome of pain‐free at two hours (z = 0.53, P = 0.10). </p> </section> <section id="CD008616-sec-0057"> <h5 class="title">Zolmitriptan 10 mg versus placebo</h5> <p>Two studies (648 participants) provided data comparing zolmitriptan 10 mg with placebo. Both studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>). </p> <p> <ul id="CD008616-list-0013"> <li> <p>The proportion of participants pain‐free at two hours with zolmitriptan 10 mg was 37% (163/439; range 36% to 39%). </p> </li> <li> <p>The proportion of participants pain‐free at two hours with placebo was 5% (10/209; range 2% to 7%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 7.8 (4.2 to 14.5; <a href="./references#CD008616-fig-0030" title="">Analysis 4.1</a>); the NNT was 3.1 (2.7 to 3.7). </p> </li> </ul> </p> <p>The oral 10 mg dose was significantly better than the oral 5 mg dose for pain‐free at two hours (z = 3.882, P = 0.0001). </p> </section> </section> <section id="CD008616-sec-0058"> <h4 class="title">Headache relief at two hours</h4> <section id="CD008616-sec-0059"> <h5 class="title">Zolmitriptan 1 mg versus placebo</h5> <p>Four studies (861 participants) provided data comparing zolmitriptan 1 mg with placebo. Three studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>), and one used a nasal spray formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>). </p> <p> <ul id="CD008616-list-0014"> <li> <p>The proportion of participants experiencing headache relief at two hours with zolmitriptan 1 mg was 55% (333/626; range 27% to 55%). </p> </li> <li> <p>The proportion of participants experiencing headache relief at two hours with placebo was 31% (183/589; range 15% to 34%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 1.8 (1.5 to 2.1) (<a href="./references#CD008616-fig-0008" title="">Analysis 1.2</a>); the NNT was 4.3 (3.3 to 5.9). </p> </li> <li> <p>For oral treatment alone the relative benefit of treatment compared to placebo was 1.6 (1.2 to 2.0) and the NNT was 5.6 (3.7 to 12). </p> </li> </ul> </p> </section> <section id="CD008616-sec-0060"> <h5 class="title">Zolmitriptan 2.5 mg versus placebo</h5> <p>Eleven studies (4904 participants or attacks) provided data comparing zolmitriptan 2.5 mg with placebo. Each of the studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0001" title="AstraZeneca . A multicentre, randomised, double‐blind trial to compare the efficacy and safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and placebo in the acute treatment of adult patients with migraine. www.astrazenecaclinicaltrials.com2005. ">311CIL/0099 2000</a>; <a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>), with one of these studies also providing information on the use of a zolmitriptan 2.5 mg nasal spray (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>). </p> <p> <ul id="CD008616-list-0015"> <li> <p>The proportion of participants experiencing headache relief at two hours with zolmitriptan 2.5 mg was 60% (1758/2921; range 54% to 67%). </p> </li> <li> <p>The proportion of participants experiencing headache relief at two hours with placebo was 29% (584/1983; range 21% to 36%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.1 (1.9 to 2.2) (<a href="#CD008616-fig-0005">Figure 5</a>: <a href="./references#CD008616-fig-0013" title="">Analysis 2.2</a>); the NNT was 3.3 (3.0 to 3.6). </p> </li> <li> <p>For oral treatment alone the relative benefit of treatment compared to placebo was 2.1 (1.9 to 2.2) and the NNT was 3.2 (3.0 to 3.5). </p> </li> </ul> </p> <div class="figure" id="CD008616-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Zolmitriptan 2.5 mg versus placebo, outcome: 2.2 Headache relief at 2 h. Studies without footnotes use the standard oral tablet." data-id="CD008616-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Zolmitriptan 2.5 mg versus placebo, outcome: 2.2 Headache relief at 2 h. Studies without footnotes use the standard oral tablet. </p> </div> </div> </div> <p>Zolmitriptan 2.5 mg was significantly better than 1 mg (z = 2.657, P = 0.008). A L'Abbé plot shows the similarity in results between studies (<a href="#CD008616-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD008616-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="L'Abbé plot showing results for zolmitriptan 2.5 mg versus placebo for headache relief at 2 hours. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence" data-id="CD008616-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>L'Abbé plot showing results for zolmitriptan 2.5 mg versus placebo for headache relief at 2 hours. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence </p> </div> </div> </div> </section> <section id="CD008616-sec-0061"> <h5 class="title">Zolmitriptan 5 mg versus placebo</h5> <p>Eleven studies (7456 participants) provided data comparing zolmitriptan 5 mg with placebo. Eight studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>), whilst the other three studies used a nasal spray formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>). </p> <p> <ul id="CD008616-list-0016"> <li> <p>The proportion of participants experiencing headache relief at two hours with zolmitriptan 5 mg was 63% (2537/4046; range 56% to 69%). </p> </li> <li> <p>The proportion of participants experiencing headache relief at two hours with placebo was 32% (1078/3410; range 15% to 43%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.0 (1.9 to 2.1; <a href="./references#CD008616-fig-0021" title="">Analysis 3.2</a>); the NNT was 3.2 (3.1 to 3.5). </p> </li> <li> <p>For oral treatment alone, the relative benefit of treatment compared to placebo was 1.9 (1.8 to 2.1) and the NNT was 3.5 (3.2 to 3.9), while for nasal spray alone, the relative benefit of treatment compared to placebo was 2.1 (1.9 to 2.2) and the NNT was 2.9 (2.6 to 3.2). </p> </li> </ul> </p> <p>The nasal spray formulation was significantly better than oral tablets for the outcome of headache relief at two hours (z = 2.746, P = 0.006). </p> </section> <section id="CD008616-sec-0062"> <h5 class="title">Zolmitriptan 10 mg versus placebo</h5> <p>Two studies (648 participants) provided data comparing zolmitriptan 10 mg with placebo. Both studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>). </p> <p> <ul id="CD008616-list-0017"> <li> <p>The proportion of participants experiencing headache relief at two hours with zolmitriptan 10 mg was 69% (302/439; range 67% to 71%). </p> </li> <li> <p>The proportion of participants experiencing headache relief at two hours with placebo was 28% (58/209; range 19% to 34%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.5 (2.0 to 3.1; <a href="./references#CD008616-fig-0031" title="">Analysis 4.2</a>); the NNT was 2.4 (2.1 to 3.0). </p> </li> </ul> </p> <p>The oral 10 mg dose was significantly better than the oral 5 mg dose for headache relief at two hours (z = 2.987, P = 0.003). </p> </section> <section id="CD008616-sec-0063"> <h5 class="title">Zolmitriptan 2.5 mg versus sumatriptan 50 mg</h5> <p>Two studies (1609 attacks) compared zolmitriptan 2.5 mg with sumatriptan 50 mg (<a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>). Both studies used oral tablets. </p> <p> <ul id="CD008616-list-0018"> <li> <p>The proportion of attacks with headache relief at two hours with zolmitriptan 2.5 mg was 66% (521/795; range 65% to 67%). </p> </li> <li> <p>The proportion of attacks with headache relief at two hours with sumatriptan 50 mg was 68% (554/814; range 64% to 71%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 0.96 (0.90 to 1.03; <a href="./references#CD008616-fig-0034" title="">Analysis 5.1</a>). There was no significant difference between treatments. </p> </li> </ul> </p> </section> <section id="CD008616-sec-0064"> <h5 class="title">Zolmitriptan 5 mg versus sumatriptan 50 mg</h5> <p>Two studies (1633 attacks) compared zolmitriptan 5 mg with sumatriptan 50 mg (<a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>). Both studies used oral tablets. </p> <p> <ul id="CD008616-list-0019"> <li> <p>The proportion of attacks with headache relief at two hours with zolmitriptan 5 mg was 67% (545/819; range 65% to 68%). </p> </li> <li> <p>The proportion of attacks with headache relief at two hours with sumatriptan 50 mg was 68% (554/814; range 64% to 71%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 0.98 (0.92 to 1.1; <a href="./references#CD008616-fig-0037" title="">Analysis 6.1</a>). There was no significant difference between treatments. </p> </li> </ul> </p> </section> </section> <section id="CD008616-sec-0065"> <h4 class="title">Headache relief at one hour</h4> <p>Two studies provided data for the 5 mg dose of the nasal spray (potentially fast‐acting) formulation for this outcome (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>). There were insufficient data for analysis of any other dose of the nasal spray, or for any dose of the oral disintegrating tablet. </p> <section id="CD008616-sec-0066"> <h5 class="title">Zolmitriptan 5 mg nasal spray versus placebo</h5> <p> <ul id="CD008616-list-0020"> <li> <p>The proportion of attacks with headache relief at one hour with zolmitriptan 5 mg nasal spray was 56% (763/1362; range 54% to 57%). </p> </li> <li> <p>The proportion of attacks with headache relief at one hour with placebo was 32% (420/1322; range 26% to 34%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 1.8 (1.6 to 1.9); the NNT was 4.2 (3.6 to 4.9) (<a href="./references#CD008616-fig-0022" title="">Analysis 3.3</a>). </p> </li> </ul> </p> </section> <section id="CD008616-sec-0067"> <h5 class="title">Zolmitriptan 5 mg oral tablets versus placebo</h5> <p>To investigate whether the nasal spray formulation was better at this early time point than the standard oral tablet, we also analysed the six studies using the same dose of standard oral tablets that reported this outcome (<a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>). </p> <p> <ul id="CD008616-list-0021"> <li> <p>The proportion of attacks with headache relief at one hour with zolmitriptan 5 mg standard oral tablets was 38% (558/1477; range 24% to 44%). </p> </li> <li> <p>The proportion of attacks with headache relief at one hour with placebo was 22% (183/833; range 15% to 27%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 1.8 (1.5 to 2.1); the NNT was 6.3 (5.1 to 8.3) (<a href="./references#CD008616-fig-0022" title="">Analysis 3.3</a>). </p> </li> </ul> </p> <p>Adding the single study that used an oral disintegrating tablet formulation (<a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>) did not change the result (RR 1.8 (1.6 to 1.9), NNT 6.1 (5.2 to 7.5)). </p> <p>The nasal spray formulation was significantly better than standard oral tablets for the outcome of headache relief at one hour (z = 3.168, P = 0.001). </p> </section> </section> <section id="CD008616-sec-0068"> <h4 class="title">Sustained pain‐free during the 24 hours postdose</h4> <section id="CD008616-sec-0069"> <h5 class="title">Zolmitriptan 2.5 mg versus placebo</h5> <p>Two studies (984 participants) provided data comparing zolmitriptan 2.5 mg with placebo. The two studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>). </p> <p> <ul id="CD008616-list-0022"> <li> <p>The proportion of participants experiencing a 24‐hour sustained pain‐free response with zolmitriptan 2.5 mg was 19% (129/694; range 15% to 24%). </p> </li> <li> <p>The proportion of participants experiencing a 24‐hour sustained pain‐free response with placebo was 6% (16/290; range 4% to 7%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 3.5 (2.1 to 5.8; <a href="./references#CD008616-fig-0014" title="">Analysis 2.3</a>); the NNT was 7.7 (6.0 to 11). </p> </li> </ul> </p> </section> <section id="CD008616-sec-0070"> <h5 class="title">Zolmitriptan 5 mg versus placebo</h5> <p>Three studies (4991 attacks) provided data comparing zolmitriptan 5 mg with placebo. One study used an oral tablet formulation (<a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>), whilst the other two studies used a nasal spray formulation (<a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>). </p> <p> <ul id="CD008616-list-0023"> <li> <p>The proportion of attacks with a 24‐hour sustained pain‐free response with zolmitriptan 5 mg was 14% (346/2516; range 11% to 23%). </p> </li> <li> <p>The proportion of attacks with a 24‐hour sustained pain‐free response with placebo was 2.9% (73/2475; range 1.6% to 7.1%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 4.7 (3.6 to 5.9; <a href="./references#CD008616-fig-0023" title="">Analysis 3.4</a>); the NNT was 9.3 (8.1 to 11). </p> </li> <li> <p>For nasal spray treatment alone, the relative benefit of treatment compared to placebo was 4.9 (3.7 to 6.5; <a href="./references#CD008616-fig-0023" title="">Analysis 3.4</a>) and the NNT was 9.6 (8.3 to 11). There was no significant difference between formulations. </p> </li> </ul> </p> </section> </section> <section id="CD008616-sec-0071"> <h4 class="title">Sustained headache relief during the 24 hours postdose</h4> <section id="CD008616-sec-0072"> <h5 class="title">Zolmitriptan 2.5 mg versus placebo</h5> <p>Four studies (2059 attacks) provided data comparing zolmitriptan 2.5 mg with placebo. Each of the four studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>), with one also providing information on the use of the zolmitriptan 2.5 mg nasal spray (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>). </p> <p> <ul id="CD008616-list-0024"> <li> <p>The proportion of attacks with 24‐hour sustained headache relief with zolmitriptan 2.5 mg was 39% (557/1436; range 31% to 46%). </p> </li> <li> <p>The proportion of attacks with 24‐hour sustained headache relief with placebo was 14% (85/623; range 10% to 22%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.9 (2.4 to 3.6; <a href="./references#CD008616-fig-0015" title="">Analysis 2.4</a>); the NNT was 4.0 (3.5 to 4.7). </p> </li> <li> <p>For oral treatment alone, the relative benefit of treatment compared to placebo was 2.9 (2.2 to 3.7) and the NNT was 4.1 (3.5 to 5.0). </p> </li> </ul> </p> </section> <section id="CD008616-sec-0073"> <h5 class="title">Zolmitriptan 5 mg versus placebo</h5> <p>Seven studies (7106 attacks) provided data comparing zolmitriptan 5 mg with placebo. Five studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>), whilst the other two studies used a nasal spray formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>). </p> <p> <ul id="CD008616-list-0025"> <li> <p>The proportion of attacks with 24‐hour sustained headache relief with zolmitriptan 5 mg was 37% (1445/3854; range 35% to 49%). </p> </li> <li> <p>The proportion of attacks with 24‐hour sustained headache relief with placebo was 12% (375/3252; range 9% to 25%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.9 (2.4 to 3.6); the NNT was 3.9 (3.6 to 4.2). </p> </li> <li> <p>For oral treatment alone, the relative benefit of treatment compared to placebo was 2.4 (2.0 to 2.8) and the NNT was 4.6 (4.0 to 5.3), while for nasal spray alone the relative benefit of treatment compared to placebo was 4.0 (3.4 to 4.6) and the NNT was 3.6 (3.3 to 3.9) (<a href="./references#CD008616-fig-0024" title="">Analysis 3.5</a>). </p> </li> </ul> </p> <p>The nasal spray formulation was significantly better than oral tablets for the outcome of sustained headache relief during the 24 hours post dose (z = 2.076, P = 0.039). </p> <p> <div class="table" id="CD008616-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Summary of results A: pain‐free and headache relief</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Attacks</b> </p> <p><b>treated</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> <p><b>(%)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo or comparator</b> </p> <p><b>(%)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative benefit (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNT</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P for difference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Pain‐free at 2 hours</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 1 mg (all formulations) versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1200</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 (2.0 to 3.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1 (5.5 to 9.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 1 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>384</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 (1.1 to 3.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (7.4 to 170)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 mg oral vs 2.5 mg oral</p> <p>z = 3.933, P = 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg (all formulations) versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5825</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (2.6 to 3.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1 (4.7 to 5.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5223</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (2.6 to 3.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0 (4.5 to 5.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg (all formulations) versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9372</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (2.7 to 3.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 (4.4 to 5.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4277</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 (2.7 to 3.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8 (4.3 to 5.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 mg oral versus 5 mg nasal</p> <p>z = 0.53, P = 0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg nasal spray versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5095</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 (2.5 to 3.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (4.2 to 5.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 10 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>648</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8 (4.2 to 14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 (2.7 to 3.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg oral versus 5 mg oral</p> <p>z = 3.882, P = 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Headache relief at 2 hours</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 1 mg (all formulations) versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>861</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8 (1.5 to 2.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3 (3.3 to 5.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 1 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>399</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (1.2 to 2.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6 (3.7 to 12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 mg oral versus 2.5 mg oral</p> <p>z = 2.657, P = 0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg (all formulations) versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4904</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1 (1.9 to 2.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (3.0 to 3.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4567</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1 (1.9 to 2.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 (3.0 to 3.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg (all formulations) versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7456</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 (1.9 to 2.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 (3.0 to 3.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4292</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 (1.8 to 2.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 (3.2 to 3.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 mg oral versus 5 mg nasal</p> <p>z = 2.746, P = 0.006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg nasal spray versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3164</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1 (1.9 to 2.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (2.6 to 3.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 10 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>648</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 (2.0 to 3.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 (2.1 to 3.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mg oral versus 5 mg oral</p> <p>z = 2.987, P = 0.003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg versus sumatriptan 50 mg (oral)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1609</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.90 to 1.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg versus sumatriptan 50 mg (oral)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1633</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.92 to 1.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Headache relief at 1 hour</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolmitriptan 5 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3584</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 (1.6 to 2.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1 (5.2 to 7.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 mg oral versus 5 mg nasal</p> <p>z = 3.284, P = 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolmitriptan 5 mg nasal spray versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2684</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 (1.6 to 1.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1 (3.6 to 4.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Sustained pain‐free during the 24 hours post dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>984</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 (2.1 to 5.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7 (5.9 to 11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg (all formulations) versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4991</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 (3.6 to 5.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 (8.1 to 11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg nasal spray versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4298</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9 (3.7 to 6.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 (8.3 to 11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Sustained headache relief during the 24 hours post dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg (all formulations) versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2059</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (2.4 to 3.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 (3.5 to 4.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1457</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (2.2 to 3.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (3.5 to 5.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg (all formulations) versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7106</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 (2.9 to 3.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (3.6 to 4.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg oral versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2827</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 (2.0 to 2.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (4.0 to 5.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 mg oral versus 5 mg nasal</p> <p>z = 2.076, P = 0.038</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg nasal spray versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4279</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0 (3.4 to 4.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.6 (3.3 to 3.9)</p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD008616-sec-0074"> <h4 class="title">Subgroup analyses of primary outcomes</h4> <p>Subgroup analyses for dose and route of administration have been carried out alongside the main analyses. Three studies (<a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>) used an oral disintegrating tablet (ODT) formulation, but only one study contributed to any analysis, so there were insufficient data for subgroup analysis. Results for ODT formulations fell within the range of the standard tablet formulation. </p> </section> <section id="CD008616-sec-0075"> <h4 class="title">Sensitivity analyses of the primary outcomes</h4> <p>Only one study (<a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a>) scored fewer than 3 points on the Oxford Quality Scale, so no sensitivity analysis could be carried out for methodological quality. Similarly, only one study (<a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>) reported data separately for participants with and without aura, so no subgroup analysis could be carried out for this subtype. </p> <p>Three studies (<a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a>) used a cross‐over design. Only with <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a> did there appear to be potential for missing data, but this study did not contribute to any meta‐analyses. Cross‐over designs may introduce other biases (<a href="./references#CD008616-bbs2-0046" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [DOI: 10.1093/ije/31.1.140] ">Elbourne 2002</a>; <a href="./references#CD008616-bbs2-0058" title="KhanKS , DayaS , JadadA . The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine1996;156(6):661‐6. ">Khan 1996</a>) but removing these studies from any analyses did not affect the results. </p> <p>None of the studies using a parallel group design had substantial amounts of missing data that might influence the results. </p> </section> <section id="CD008616-sec-0076"> <h4 class="title">Adverse events</h4> <p>All except one study reported on the number of participants experiencing any adverse events after treatment; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a> did not report adverse events for the placebo group, so no comparison could be made. Most studies appeared to collect data using spontaneous reports in diary cards and at follow‐up review after the end of treatment. <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>, <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>, <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>, and <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a> did not provide any details of the method of adverse event data collection. The duration over which data were collected was not always specified and, where it was, there were differences between studies. Most studies probably collected data during the 24 hours following treatment, but <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a> specified 48 hours, <a href="./references#CD008616-bbs2-0020" title="SolomonGD , CadyRK , KlapperJA , EarlNL , SaperJR , RamadanNM . Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology1997;49(5):1219‐25. ">Solomon 1997</a> and <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a> 7 days, and <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a> 10 days. <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a> collected data for 24 hours for non‐serious adverse events and 7 days for serious events, while <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a> reported only events that were considered 'treatment‐related'. </p> <p>In some studies a second dose of study medication was taken, and in all studies rescue medication was allowed if there was an inadequate response after a given period of time. It was likely that in all cases adverse event data continued to be collected after such additional medication. <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a> reported adverse event data according to the total dose of study medication taken. </p> <p>A number of studies treated more than one attack. In <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>, first‐attack data were reported for adverse events, while <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>, <a href="./references#CD008616-bbs2-0010" title="GeraudG , CompagnonA , RossiA , COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double‐blind, randomised, three‐attack study. European Neurology2002;47(2):88‐98. ">Geraud 2002</a>, and <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a> reported events in all attacks combined. <a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>, <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>, <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>, and <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a> reported events per treatment group, but it was unclear how multiple attacks were combined. </p> <p>Despite these inconsistencies, we have included as much data as possible in the adverse event analyses in order to be more inclusive and conservative (<a href="./appendices#CD008616-sec-0104">Appendix 6</a>). See 'Summary of results B' and 'Summary of results C' for adverse event results. </p> <p>Treatments were generally described as well‐tolerated, with most adverse events being of mild or moderate severity and self‐limiting. </p> </section> <section id="CD008616-sec-0077"> <h4 class="title">Participants experiencing any adverse event</h4> <section id="CD008616-sec-0078"> <h5 class="title">Zolmitriptan 1 mg versus placebo</h5> <p>Three studies (856 attacks) comparing zolmitriptan 1 mg with placebo provided data. Two studies used an oral tablet (<a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>) and one used a nasal spray formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>). </p> <p> <ul id="CD008616-list-0026"> <li> <p>The proportion of attacks with adverse events with zolmitriptan 1 mg was 31% (132/431; range 15% to 39%). </p> </li> <li> <p>The proportion of attacks with adverse events with placebo was 24% (103/425; range 14% to 30%). </p> </li> <li> <p>The relative harm of treatment compared with placebo was 1.3 (1.01 to 1.6; <a href="./references#CD008616-fig-0009" title="">Analysis 1.3</a>); the NNH was 16 (8.1 to 230). </p> </li> </ul> </p> </section> <section id="CD008616-sec-0079"> <h5 class="title">Zolmitriptan 2.5 mg versus placebo</h5> <p>Twelve studies (6055 attacks) comparing zolmitriptan 2.5 mg with placebo provided data. Each of the 11 studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a>; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a>, <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0020" title="SolomonGD , CadyRK , KlapperJA , EarlNL , SaperJR , RamadanNM . Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology1997;49(5):1219‐25. ">Solomon 1997</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>), with one also using a nasal spray formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>). </p> <p> <ul id="CD008616-list-0027"> <li> <p>The proportion of attacks with adverse events with zolmitriptan 2.5 mg was 32% (1167/3628; range 16% to 63%). </p> </li> <li> <p>The proportion of attacks with adverse events with placebo was 17% (422/2427; range 9% to 40%). </p> </li> <li> <p>The relative harm of treatment compared with placebo was 1.7 (1.6 to 1.9; <a href="./references#CD008616-fig-0016" title="">Analysis 2.5</a>); the NNH was 6.8 (5.9 to 7.9). </p> </li> </ul> </p> </section> <section id="CD008616-sec-0080"> <h5 class="title">Zolmitriptan 5 mg versus placebo</h5> <p>Ten studies (9072 attacks) comparing zolmitriptan 5 mg with placebo provided data. Seven studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>), whilst the other three studies used a nasal spray formulation (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>). </p> <p> <ul id="CD008616-list-0028"> <li> <p>The proportion of attacks with adverse events with zolmitriptan 5 mg was 41% (2101/5065; range 20% to 61%). </p> </li> <li> <p>The proportion of attacks with adverse events with placebo was 19% (742/4007; range 9% to 34%). </p> </li> <li> <p>The relative harm of treatment compared with placebo was 2.2 (2.0 to 2.3; <a href="./references#CD008616-fig-0025" title="">Analysis 3.6</a>); the NNH was 4.4 (4.0 to 4.7). </p> </li> <li> <p>For oral treatment alone, the relative harm of treatment compared to placebo was 2.0 (1.8 to 2.2) and the NNH was 4.6 (4.2 to 5.3), while for nasal spray alone the relative benefit of treatment compared to placebo was 2.4 (2.1 to 2.6) and the NNH was 4.2 (3.8 to 4.7) (<a href="./references#CD008616-fig-0025" title="">Analysis 3.6</a>). </p> </li> </ul> </p> <p>There was no statistically significant difference between the two formulations for participants experiencing any adverse events. </p> </section> <section id="CD008616-sec-0081"> <h5 class="title">Zolmitriptan 10 mg versus placebo</h5> <p>Two studies (736 participants) comparing zolmitriptan 10 mg with placebo provided data. Both studies used an oral tablet formulation (<a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>). </p> <p> <ul id="CD008616-list-0029"> <li> <p>The proportion of participants experiencing adverse events with zolmitriptan 10 mg was 71% (352/499; range 67% to 75%). </p> </li> <li> <p>The proportion of participants experiencing adverse events with placebo was 32% (75/237; range 30% to 34%). </p> </li> <li> <p>The relative harm of treatment compared with placebo was 2.2 (1.8 to 2.7; <a href="./references#CD008616-fig-0032" title="">Analysis 4.3</a>); the NNH was 2.6 (2.2 to 3.2). </p> </li> </ul> </p> </section> <section id="CD008616-sec-0082"> <h5 class="title">Zolmitriptan 2.5 mg versus sumatriptan 50 mg</h5> <p>Two studies (1771 attacks) comparing zolmitriptan 2.5 mg with sumatriptan 50 mg provided data. Both studies used oral tablet formulations (<a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>). </p> <p> <ul id="CD008616-list-0030"> <li> <p>The proportion of attacks with adverse events with zolmitriptan 2.5 mg was 32% (283/878; range 28% to 35%). </p> </li> <li> <p>The proportion of attacks with adverse events with sumatriptan 50 mg was 28% (251/893; range 18% to 34%). </p> </li> <li> <p>The relative harm of treatment compared with placebo was 1.1 (0.99 to 1.3; <a href="./references#CD008616-fig-0035" title="">Analysis 5.2</a>). The NNH was not calculated. </p> </li> </ul> </p> </section> <section id="CD008616-sec-0083"> <h5 class="title">Zolmitriptan 5 mg versus sumatriptan 50 mg</h5> <p>Two studies (1789 attacks) comparing zolmitriptan 5 mg with sumatriptan 50 mg provided data. Both studies used oral tablet formulations (<a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>). </p> <p> <ul id="CD008616-list-0031"> <li> <p>The proportion of attacks with adverse events with zolmitriptan 5 mg was 31% (280/896; range 21% to 38%). </p> </li> <li> <p>The proportion of attacks with adverse events with sumatriptan 50 mg was 28% (251/893; range 18% to 34%). </p> </li> <li> <p>The relative harm of treatment compared with placebo was 1.1 (0.96 to 1.3; <a href="./references#CD008616-fig-0038" title="">Analysis 6.2</a>). The NNH was not calculated. </p> </li> </ul> </p> <p> <div class="table" id="CD008616-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Summary of results B: number of participants experiencing any adverse event (all formulations)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Zolmitriptan (%)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator (%)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative risk (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNH (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P for difference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 1 mg versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>856</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 (1.01 to 1.6 )</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (8.1 to 230)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg v 2.5 mg</p> <p>z = 2.596, P = 0.010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5489</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 (1.6 to 1.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8 (5.9 to 7.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 mg v 5 mg</p> <p>z = 5.718, P &lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9072</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (2.0 to 2.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4 (4.0 to 4.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg v 10 mg</p> <p>z = 4.236, P &lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 10 mg versus placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>736</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (1.8 to 2.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 (2.2 to 3.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 2.5 mg versus sumatriptan 50 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1771</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 (0.99 to 1.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zolmitriptan 5 mg versus sumatriptan 50 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1789</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 (0.96 to 1.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> </div> </p> <p>There was a clear dose response relationship for zolmitriptan in comparisons with placebo, with significantly more participants experiencing adverse events with each dose increment. Excluding studies that reported over periods greater than 24 hours did not significantly change the results. There was no significant difference between zolmitriptan 5 mg and sumatriptan 50 mg. </p> </section> </section> <section id="CD008616-sec-0084"> <h4 class="title">Participants experiencing serious adverse events</h4> <p>Three studies did not specifically comment on serious adverse events (<a href="./references#CD008616-bbs2-0011" title="AllaisG , AcutoG , CabarrocasX , EsbriR , BenedettoC , BussoneG . Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences2006;27 Suppl 2:S193‐7. [DOI: 10.1007/s10072‐006‐0600‐4] GoadsbyPJ , MassiouH , PascualJ , DienerHC , DahlöfCG , MateosV . Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurologica Scandinavica2007;115(1):34‐40. ">Goadsby 2007b</a>; <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>), four reported that there were none during the study (<a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>), and two reported that there were no drug‐related serious adverse events (<a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0020" title="SolomonGD , CadyRK , KlapperJA , EarlNL , SaperJR , RamadanNM . Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology1997;49(5):1219‐25. ">Solomon 1997</a>). The remaining 17 studies all reported at least one serious adverse event, although most occurred outside the 24‐hour post dose window, and most were judged to be unrelated to any study medication. </p> <p>In studies reporting occurrence of serious adverse events separately for the zolmitriptan and placebo treatment arms (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a>; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a>; <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>), or the absence of such events (<a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>), the incidence was ≤ 1% in any treatment arm, and overall was 0.33% (22/6647) for all doses ≥ 1 mg (including second doses and rescue medication) and all formulations of zolmitriptan combined, and 0.20% (8/3914) for placebo. There was no evidence of a dose response relationship, and there were too few events to calculate RR or NNH. Further details of individual studies are in <a href="./appendices#CD008616-sec-0104">Appendix 6</a>. </p> </section> <section id="CD008616-sec-0085"> <h4 class="title">Withdrawals due to adverse events</h4> <p>Ten studies either did not specifically report on adverse event withdrawals, did not report data for each treatment arm separately, or did not report clearly either whether the percentage referred to patients or attacks, or how multiple attacks were handled (<a href="./references#CD008616-bbs2-0001" title="AstraZeneca . A multicentre, randomised, double‐blind trial to compare the efficacy and safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and placebo in the acute treatment of adult patients with migraine. www.astrazenecaclinicaltrials.com2005. ">311CIL/0099 2000</a>; <a href="./references#CD008616-bbs2-0003" title="DahlöfC , DienerHC , GoadsbyPJ , MassiouH , OlesenJ , SchoenenJ , et al. Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study. Eurean Journal of Neurology1998;5(6):535‐43. ">Dahlof 1998</a>; <a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a>; <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0018" title="RyanRE , DiamondS , GiammarcoRAM , AuroraSK , ReedRC , FletcherPE . Efficacy of zolmitriptan at early time‐points for the acute treatment of migraine and treatment recurrence. A randomised, placebo‐controlled trial. CNS Drugs2000;13(3):215‐26. ">Ryan 2000</a>; <a href="./references#CD008616-bbs2-0019" title="SakaiF , IwataM , TashiroK , ItoyamaY , TsujiS , FukuuchiY , et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose‐response study. Cephalalgia2002;22(5):376‐83. ">Sakai 2002</a>; <a href="./references#CD008616-bbs2-0020" title="SolomonGD , CadyRK , KlapperJA , EarlNL , SaperJR , RamadanNM . Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology1997;49(5):1219‐25. ">Solomon 1997</a>; <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a>). The remaining studies reported the number of withdrawals per treatment group. </p> <p>In studies reporting the occurrence of adverse event withdrawals separately for zolmitriptan and placebo treatment arms (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a>; <a href="./references#CD008616-bbs2-0021" title="SpieringsEL , RapoportAM , DodickDW , CharlesworthB . Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs2004;18(15):1133‐41. ">Spierings 2004</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>), or the absence of such withdrawals (<a href="./references#CD008616-bbs2-0006" title="DowsonAJ , MacGregorEA , PurdyRA , BeckerWJ , GreenJ , LevySL . Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia2002;22(2):101‐6. ">Dowson 2002</a>; <a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a>; <a href="./references#CD008616-bbs2-0016" title="PascualJ , VegaP , DienerHC , AllenC , VrijensF , PatelK . Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan‐Zolmitriptan Study Group. Cephalalgia2000;20(5):455‐61. ">Pascual 2000</a>; <a href="./references#CD008616-bbs2-0017" title="RapoportAM , RamadanNM , AdelmanJU , MathewNT , ElkindAH , KudrowDB , et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double‐blind, placebo‐controlled, dose range‐finding study. The 017 Clinical Trial Study Group. Neurology1997;49(5):1210‐8. ">Rapoport 1997</a>; <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>), the incidence was ≤ 2.1% in any treatment arm, and overall was 0.65% (35/5346) for all doses ≥ 1 mg (including second doses and rescue medication) and formulations of zolmitriptan combined, and 0.20% (7/3428) for placebo. There was no evidence of a dose response relationship, and there were too few events to calculate relative risk or NNH. </p> <p>Four studies with active comparators reported adverse event withdrawals: <a href="./references#CD008616-bbs2-0010" title="GeraudG , CompagnonA , RossiA , COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double‐blind, randomised, three‐attack study. European Neurology2002;47(2):88‐98. ">Geraud 2002</a> for zolmitriptan versus aspirin plus metoclopramide, <a href="./references#CD008616-bbs2-0011" title="AllaisG , AcutoG , CabarrocasX , EsbriR , BenedettoC , BussoneG . Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences2006;27 Suppl 2:S193‐7. [DOI: 10.1007/s10072‐006‐0600‐4] GoadsbyPJ , MassiouH , PascualJ , DienerHC , DahlöfCG , MateosV . Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurologica Scandinavica2007;115(1):34‐40. ">Goadsby 2007b</a> for zolmitriptan versus almotriptan, and <a href="./references#CD008616-bbs2-0007" title="GallagherRM , DennishG , SpieringsEL , ChitraR . A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache2000;45(1):7‐16. ">Gallagher 2000</a> and <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a> for zolmitriptan versus sumatriptan. There was no significant difference between zolmitriptan 2.5 mg or 5 mg and sumatriptan 50 mg in these two studies that treated up to six attacks. </p> </section> <section id="CD008616-sec-0086"> <h4 class="title">Other withdrawals</h4> <p>In most studies withdrawals due to reasons other than adverse events were well documented and included protocol violations, loss on follow‐up, withdrawal of consent, lack of efficacy, and lack of qualifying attacks. However, other studies did not provide detailed information or specify withdrawals by group, and in certain cases it was unclear if withdrawal had occurred before or after taking the study medication. The number of withdrawals was not likely to affect estimates of efficacy or harm. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008616-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008616-sec-0087"></div> <section id="CD008616-sec-0088"> <h3 class="title" id="CD008616-sec-0088">Summary of main results</h3> <p>This review included 25 randomised, double‐blind, controlled studies with 20,162 participants. Fourteen studies had only a placebo control, six had both placebo control and an active comparator, and five had an active comparator only. Active comparators were ketoprofen, sumatriptan, acetylsalicylic acid plus metoclopramide, almotriptan, telcagepant, rizatriptan, eletriptan and frovatriptan. Included studies used zolmitriptan at doses of 0.5, 1, 2.5, 5, 10, 15, 20, and 25 mg in an oral tablet (either standard or disintegrating) or nasal spray formulation. Most of the data were for the 2.5 mg and 5 mg doses, and for the standard oral tablet. In most studies participants treated established attacks of moderate to severe intensity, and there were insufficient data for any analysis of treatment when pain was still mild. </p> <p>For all efficacy outcomes zolmitriptan was superior to placebo, and doses of 2.5 mg or more gave clinically useful NNTs for all outcomes. The remarkably consistent response between studies for the primary outcomes, as illustrated by L'Abbe plots, was not unexpected given the inclusion criteria for the studies and the well‐defined outcomes. There was a trend for lower (better) NNTs at higher doses, with significant differences between 10 mg and 5 mg oral zolmitriptan for pain‐free at two hours, and headache relief at two hours. There were no significant differences between oral zolmitriptan 5 mg and 2.5 mg for any of the primary efficacy outcomes. There was no difference between oral and nasal spray formulation at the 5 mg dose, and insufficient data to compare oral with nasal spray formulations at other doses. </p> <p>For the IHS preferred outcome of pain‐free at two hours, zolmitriptan 2.5 mg, 5 mg, and 10 mg (oral formulations) compared to placebo gave NNTs of 4.9, 4.8, and 3.1 respectively. About 30% to 40% of participants were responders with zolmitriptan compared to 5% to 10% with placebo. For headache relief at two hours the NNTs were 3.2, 3.5, and 2.4, respectively (60% to 70% responders with zolmitriptan, 30% with placebo). For sustained headache relief during the 24 hours post dose the NNTs for 2.5 mg and 5 mg were about 4 and for sustained pain‐free they were 8 to 9. </p> <p>Analysis of adverse events was compromised by the fact that some studies did not specify the time period over which the data were collected, and some specified time periods different from the 24‐hour period specified in the protocol. Furthermore, studies allowed use of rescue medication for inadequate response (usually after two hours), and many allowed a second dose of study medication for headache recurrence (or sometimes lack of efficacy), and did not specify whether adverse event data continued to be collected from participants who had taken additional medication. It is likely that they were, so comparisons between doses and with placebo may not be reliable. With these caveats, we chose to pool as much data as possible. More participants experienced adverse events with zolmitriptan than with placebo, and a dose response relationship was seen over the range 1 mg to 10 mg, with NNHs of 16 to 2.6. For the most part adverse events were described as of mild to moderate intensity, and self‐limiting. Serious adverse events were uncommon and only one was reported as related to a study drug, in this case aspirin plus metoclopramide. </p> <p>Specific adverse events occurred more often with zolmitriptan than with placebo, and for somnolence, asthenia, dizziness or vertigo, paraesthesia, and vasodilation or warm sensation or flush, there were clear dose response relationships, with significant differences between 2.5 mg and 5 mg, and 5 mg and 10 mg for most events. Taste disturbance was a problem with the intranasal formulation, with an NNH of 6.6 during the 24 hours postdose for zolmitriptan 5 mg. </p> <p>Recurrence of headache following an initial response is perceived to be a problem with triptans, and its impact is probably best judged using outcomes of sustained pain‐free and sustained headache relief during the 24 hours postdose (without use of rescue medication). These outcomes were not reported in all the included studies. Available data indicate that approximately two‐thirds of those who experience headache relief at two hours will sustain that response for 24 hours with zolmitriptan, compared to half with placebo, while half to one‐third who are pain‐free at two hours will sustain that response for 24 hours with zolmitriptan compared to half with placebo. There was no difference between the 2.5 mg and 5 mg doses, and only one study reported findings for 10 mg. Slightly fewer than 40% (2 in 5) of participants experienced sustained headache relief and 14% (1 in 7) sustained pain‐free responses, without use of rescue medication. </p> <p>Amongst the active comparators, only sumatriptan 50 mg was evaluated in more than one study. There were no significant differences between zolmitriptan 2.5 mg and sumatriptan 50 mg or zolmitriptan 5 mg and sumatriptan 50 mg for headache relief at two hours, any adverse event, or withdrawals due to adverse events. </p> <p>Additional analyses (<a href="./appendices#CD008616-sec-0105">Appendix 7</a>) show that almost twice as many participants (63%) treated with placebo used rescue medication than with zolmitriptan 2.5 mg or 5 mg (35%). Data were available for relief of associated symptoms of nausea, photophobia and phonophobia, but vomiting occurred too infrequently for reliable analysis. Zolmitriptan 2.5 mg and 5 mg compared with placebo gave NNTs of about 7 for relief of nausea at 2 hours, and 4 for relief of either photophobia or phonophobia. Approximately half of the participants treated with zolmitriptan achieved relief of these symptoms, compared with one in three or one in four with placebo. </p> </section> <section id="CD008616-sec-0089"> <h3 class="title" id="CD008616-sec-0089">Overall completeness and applicability of evidence</h3> <p>Included participants suffered from migraine in accordance with IHS criteria, with around one to six attacks per month, and a history of attacks for at least six months, and usually one year. In the majority of studies the intensity of treated attacks had to be greater than moderate when medication was taken. In most studies stable prophylactic medication was allowed. However, some papers did not mention the use of prophylactics, and two studies (<a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0025" title="VisserWH , KleinKB , CoxRC , JonesD , FerrariMD . 311C90, a new central and peripherally acting 5‐HT1D receptor agonist in the acute oral treatment of migraine: a double‐blind, placebo‐controlled, dose‐range finding study. Neurology1996;46(2):522‐6. ">Visser 1996</a>) included only participants who were not taking prophylactics. <a href="./references#CD008616-bbs2-0009" title="GeraudG , OlesenJ , PfaffenrathV , Tfelt‐HansenP , ZuppingR , DienerHC , et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia2000;20(1):30‐8. ">Geraud 2000</a> required participants to be triptan‐naïve, <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a> excluded those who had a previous inadequate response to at least two triptans, and <a href="./references#CD008616-bbs2-0022" title="SteinerTJ , DienerHC , MacGregorEA , SchoenenJ , MuirheadsN , SikesCR . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia2003;23(10):942‐52. ">Steiner 2003</a> excluded people who were consistently resistant to all treatments. Overall there did not appear to be a particular bias towards a certain type of migraine patient, but many studies recruited participants through headache clinics, which may have selected for those with more severe or hard‐to‐treat pain. Individuals were carefully screened before study entry, and those with certain conditions, particularly cardio‐ or cerebrovascular disease, were excluded from the studies. Other exclusions included pregnant or lactating women and individuals with renal or hepatic disease, or who regularly experienced vomiting, together with individuals who suffered from frequent non‐migraine headaches or basilar, ophthalmoplegic or hemiplegic migraine. This may mean that the study population is not a reflection of a less carefully screened general population who may be prescribed zolmitriptan. </p> <p>While most studies reported IHS preferred outcomes, they did not all report all the outcomes of interest for this review so that numbers of participants in any comparison were usually smaller than the numbers treated. </p> <p>Although zolmitriptan was compared with a number of different active comparators, most were used in only one study each, so that no analysis was possible except for zolmitriptan 2.5 mg and 5 mg versus sumatriptan 50 mg. </p> <p>Single‐dose studies provide only limited information about adverse events, and individual studies are generally underpowered to assess harm, but pooling adverse event data from similar studies may allow more robust estimates for short‐term use. In these studies the number of participants who experienced any adverse events was slightly increased with zolmitriptan compared to placebo. However, it is important to remember that in many studies rescue medication or a second dose of study medication was permitted if the study medication did not provide relief, or in the event of recurrence, and this may disproportionately increase the rates of adverse events in the placebo group. Some studies in this review reported data for individual adverse events only if they occurred at a specified rate, which differed between studies (&gt; 1% to ≥ 5%); this inevitably means that some events occurring at lower frequencies were not reported in some studies. </p> <p>Only three studies (<a href="./references#CD008616-bbs2-0008" title="GawelM , AschoffJ , MayA , CharlesworthBR , REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine‐‐results from phase 1 of the REALIZE Study. Headache2005;45(1):7‐16. ">Gawel 2005</a>; <a href="./references#CD008616-bbs2-0014" title="KlapperJ , LucasC , RøsjøØ , CharlesworthB , ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia2004;24(11):918‐24. ">Klapper 2004</a>; <a href="./references#CD008616-bbs2-0015" title="LoderE , FreitagFG , AdelmanJ , PearlmandS , Abu‐ShakraS . Pain‐free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double‐blind placebo‐ controlled trial. Current Medical Research and Opinion2005;21(3):381‐9. ">Loder 2005</a>) allowed participants to treat a migraine attack of mild severity. However, in clinical practice most people treat their headache when it first begins and often this means the pain is mild. There is also some evidence that treating attacks in the early stages is beneficial (<a href="./references#CD008616-bbs2-0048" title="GendollaA . Early treatment in migraine: how strong is the current evidence?. Cephalalgia2008;28 Suppl 2:28‐35. [DOI: 10.1111/j.1468‐2982.2008.01688.x] ">Gendolla 2008</a>). </p> </section> <section id="CD008616-sec-0090"> <h3 class="title" id="CD008616-sec-0090">Quality of the evidence</h3> <p>The majority of included studies were of good quality. However, 18 studies did not adequately describe sequence generation, 18 studies did not provide information about allocation concealment, and seven studies did not provide details on the method of blinding. In a number of studies withdrawals and drop‐outs were not reported adequately by treatment group, and for some outcomes, reported denominators differed from the intention‐to‐treat (ITT) population, presumably because some participants failed to record data at that point. Wherever an adequate explanation was not given we have used the ITT denominator if it gave a more conservative estimate; in general, the number of missing participants was not sufficient to significantly alter the results. Thirteen studies had at least 200 participants in each treatment arm, a further 11 had between 50 and 200 in one or more treatment arms (the placebo arm was often smallest with other treatment arms having over 200 participants), and one had fewer than 50 participants in all treatment arms. The overall methodological quality of the included studies was good, and treatment group sizes were sufficiently large to avoid major bias in the results for efficacy. </p> <p>While most studies used patient diaries and reported some information about adverse events, the outcomes were not always our preferred ones, and the time over which data were collected was frequently not explicit. It is likely that data continued to be collected after intake of rescue medication or a second dose of study medication, so that the total dose over the period assessed is uncertain. </p> </section> <section id="CD008616-sec-0091"> <h3 class="title" id="CD008616-sec-0091">Potential biases in the review process</h3> <p>We identified a large amount of data in comparisons with placebo, particularly for the 2.5 mg and 5 mg doses. Almost 3800 participants would have to have been involved in unpublished trials with zero treatment effects for the NNT for headache relief at two hours to increase to 6 or more (which we considered the limit of clinical utility in this situation) for the 2.5 mg dose (<a href="./references#CD008616-bbs2-0067" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). This is equivalent to 10 studies with 380 participants in each, or 5 with 760 participants. Similarly over 3300 additional participants would be needed in trials with zero effect to increase the NNT for pain‐free at two hours to 8 or more. It is unlikely, but not impossible, that this amount of unidentified data exists. We know of one apparently unpublished cross‐over study, involving 126 participants treated with zolmitriptan nasal spray 5 mg and placebo (<a href="./references#CD008616-bbs2-0030" title="Dr Avanti Biniwale (Principleinvestigator) . A Clinical Trial to evaluate efficacy and safety of zolmitriptan 5 mg nasal spray in acute treatment of migraine. http://ctri.nic.in (accessed 13 November 2013)2013. [CTRI/2009/091/000196] ">CTRI/2009/091/000196</a>), but this study reported that the results were similar to published studies. </p> <p>The methods of review were such as to minimise bias due to the review process itself, but use of data from both phases of cross‐over studies and from studies reporting combined data from several attacks may introduce unknown biases (<a href="./references#CD008616-bbs2-0046" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [DOI: 10.1093/ije/31.1.140] ">Elbourne 2002</a>). For cross‐over studies a 48‐hour period between qualifying attacks should limit the potential for carry‐over effects, and for multiple attacks there is some evidence of consistency of response (in terms of proportion of participants achieving the outcome) for aspirin in migraine (<a href="./references#CD008616-bbs2-0059" title="KirthiV , DerryS , MooreRA , McQuayHJ . Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008041.pub3] ">Kirthi 2013</a>) and within some studies in this review (<a href="./references#CD008616-bbs2-0002" title="CharlesworthBR , DowsonAJ , PurdyA , BeckerWJ , Boes‐HansenS , FärkkiläM . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled, dose‐ranging study versus zolmitriptan tablet. CNS Drugs2003;17(9):653‐67. ">Charlesworth 2003</a>; <a href="./references#CD008616-bbs2-0005" title="DodickD , BrandesJ , ElkindA , MathewN , RodichokL . Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double‐blind, placebo‐controlled study. CNS Drugs2005;19(2):125‐36. ">Dodick 2005</a>; <a href="./references#CD008616-bbs2-0012" title="Gruffyd‐JonesK , KiesB , MiddletonA , MulderLJ , RøsjøØ , MillsonDS . Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double‐blind, international study. European Journal of Neurology2001;8(3):237‐45. ">Gruffyd‐Jones 2001</a>). </p> <p>We specified that a minimum of 200 participants in at least two studies were required before carrying out any pooled analysis, but ideally we would need at least 200 participants in each treatment arm where there is an event rate of 50% to be reasonably confident in the size of an effect (<a href="./references#CD008616-bbs2-0068" title="MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. ‘‘Evidence” in chronic pain – establishing best practice in the reporting of systematic reviews. Pain2010;150:386–389. ">Moore 2010</a>). The magnitude of effect for outcomes with fewer participants or lower event rates should be interpreted with caution. </p> </section> <section id="CD008616-sec-0092"> <h3 class="title" id="CD008616-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD008616-bbs2-0071" title="OldmanAD , SmithLA , McQuayHJ , MooreRA . Pharmacological treatments for acute migraine: quantitative systematic review. Pain2002;97(3):247‐57. [DOI: 10.1016/S0304‐3959(02)00024‐6] ">Oldman 2002</a> reviewed all pharmacological treatments for acute migraine, including four studies involving zolmitriptan, all of which are included here. Results are presented as the proportion responding, relative risk and NNT, and are broadly consistent with those found in this review for the 5 mg dose: NNTs for headache relief at two hours are very similar, but our estimate for pain‐free at two hours is higher (worse), and we found a significant difference from placebo for sustained headache relief during the 24 hours post dose. Results for the 2.5 mg dose differ more from ours, probably because only two studies (maximum 651 participants) contributed data in the 2002 review. Adverse events were not analysed by Oldman et al. because of poor reporting, on which we have commented in this review. </p> <p><a href="./references#CD008616-bbs2-0047" title="FerrariMD , GoadsbyPJ , RoonKI , LiptonRB . Triptans (serotonin, 5‐HT1B/1D agonists) in migraine: detailed results and methods of a meta‐analysis of 53 trials. Cephalalgia2002;22(8):633‐58. [DOI: 10.1046/j.1468‐2982.2002.00404.x] ">Ferrari 2002</a> carried out a meta‐analysis of all triptans for acute migraine, reviewing nine studies (three unpublished at the time of the review) involving zolmitriptan, all of which are included here. Results were presented as absolute or placebo‐subtracted event rates, or both; they are consistent with those found in this review. NNTs were not calculated. </p> <p><a href="./references#CD008616-bbs2-0037" title="ChenLC , AshcroftDM . Meta‐analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache2008;48(2):236‐47. [DOI: 10.1111/j.1526‐4610.2007.01007.x] ">Chen 2007</a> carried out a meta‐analysis of zolmitriptan for acute migraine, including 24 studies. Three of these studies did not satisfy the inclusion criteria for our review (one was an abstract, one examined a second dose of medication for persistent headache, and one enrolled only adolescents), and we have included four additional studies (<a href="./references#CD008616-bbs2-0004" title="DibM , MassiouH , WeberM , HenryP , Garcia‐AcostaS , BousserMG , Bi‐Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double‐blind randomized clinical trial. Neurology2002;58(11):1660‐5. ">Dib 2002</a>; <a href="./references#CD008616-bbs2-0013" title="DodickDW , KostJ , AssaidC , LinesC , HoTW . Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient‐level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia2011;31(3):296‐300. [DOI: 10.1177/0333102410385585] HoTW , FerrariMD , DodickDW , GaletV , KostJ , FanX , et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo‐controlled, parallel‐treatment trial. Lancet2008;372(9656):2115‐23. ">Ho 2008</a>; <a href="./references#CD008616-bbs2-0023" title="TuchmanM , HeeA , EmeribeU , SilbersteinS . Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs2006;20(12):1019‐26. ">Tuchman 2006</a>; <a href="./references#CD008616-bbs2-0024" title="AllaisG , TulloV , BenedettoC , ZavaD , OmboniS , BussoneG . Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double‐blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences2011;32 Suppl 1:S99‐104. [DOI: 10.1007/s10072‐011‐0547‐y] TulloV , AllaisG , CuroneM , FerrariMD , OmboniS , BenedettoC , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2012;33 Suppl 1:S61‐4. [DOI: 10.1007/s10072‐012‐1043‐8] TulloV , AllaisG , FerrariMD , CuroneM , MeaE , OmboniS , et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double‐blind, randomized, multicenter, Italian study. Neurological Sciences2010;31 Suppl 1:S51‐4. ">Tullo 2010</a>). Results were presented as relative risk, calculated using random effects; their results for relative risk are generally slightly lower than those in this review in comparisons with placebo, except for zolmitriptan 5 mg nasal spray, which are significantly higher. NNTs were not reported. With the exception of sumatriptan (two studies), all other active comparisons were made with data from one study only; we chose not to do this since results from only one study are highly susceptible to random chance. Relative risks for adverse events are again similar to this review, except for the 5 mg nasal spray. </p> <p>None of these earlier reviews reported on use of rescue medication or relief of associated symptoms. </p> <p><a href="./references#CD008616-bbs2-0031" title="AmanzioM , CorazziniLL , VaseL , BenedettiF . A systematic review of adverse events in placebo groups of anti‐migraine clinical trials. Pain2009;146(3):261‐9. [DOI: 10.1016/j.pain.2009.07.010] ">Amanzio 2009</a> carried out a systematic review of placebo groups in trials of acute migraine treatment where active agents included triptans, NSAIDs, and anticonvulsants. Results for zolmitriptan were not reported separately, and the review did not take account of the complexities and problems of adverse event reporting in migraine trials, commented on above. A multiple treatment comparison meta‐analysis (network meta‐analysis) using the same efficacy outcomes as here concluded that zolmitriptan had the second best efficacy, after rizatriptan (<a href="./references#CD008616-bbs2-0079" title="ThorlundK , MillsEJ , WuP , RamosE , ChatterjeeA , DruytsE . Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta‐analysis. Cephalalgia2014;34(4):258‐67. [DOI: 10.1177/0333102413508661] ">Thorlund 2014</a>). The methods in the network meta‐analysis did not allow comparison with this review directly, but the general thrust of the results was compatible with the results of this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008616-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD008616-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008616-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Zolmitriptan 2.5 mg versus placebo, outcome: 2.1 Pain‐free at 2 h. Studies without footnotes use the standard oral tablet." data-id="CD008616-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Zolmitriptan 2.5 mg versus placebo, outcome: 2.1 Pain‐free at 2 h. Studies without footnotes use the standard oral tablet. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="L'Abbé plot showing results for zolmitriptan 2.5 mg versus placebo for pain‐free at 2 hours. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence" data-id="CD008616-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>L'Abbé plot showing results for zolmitriptan 2.5 mg versus placebo for pain‐free at 2 hours. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Zolmitriptan 2.5 mg versus placebo, outcome: 2.2 Headache relief at 2 h. Studies without footnotes use the standard oral tablet." data-id="CD008616-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Zolmitriptan 2.5 mg versus placebo, outcome: 2.2 Headache relief at 2 h. Studies without footnotes use the standard oral tablet. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="L'Abbé plot showing results for zolmitriptan 2.5 mg versus placebo for headache relief at 2 hours. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence" data-id="CD008616-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>L'Abbé plot showing results for zolmitriptan 2.5 mg versus placebo for headache relief at 2 hours. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 1 Pain‐free at 2 h." data-id="CD008616-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 1 Pain‐free at 2 h.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 2 Headache relief at 2 h." data-id="CD008616-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 2 Headache relief at 2 h.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 3 Any adverse event." data-id="CD008616-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 3 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 4 Use of rescue medication." data-id="CD008616-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 4 Use of rescue medication.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 5 Relief of associated symptoms at 2 h." data-id="CD008616-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Zolmitriptan 1 mg versus placebo, Outcome 5 Relief of associated symptoms at 2 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 1 Pain‐free at 2 h." data-id="CD008616-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 1 Pain‐free at 2 h.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 2 Headache relief at 2 h." data-id="CD008616-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 2 Headache relief at 2 h.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 3 24‐h sustained pain‐free." data-id="CD008616-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 3 24‐h sustained pain‐free.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 4 24‐h sustained headache relief." data-id="CD008616-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 4 24‐h sustained headache relief. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 5 Any adverse event." data-id="CD008616-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 5 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 6 Specific adverse events." data-id="CD008616-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 6 Specific adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 7 Use of rescue medication." data-id="CD008616-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 7 Use of rescue medication.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 8 Relief of associated symptoms at 2 h." data-id="CD008616-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Zolmitriptan 2.5 mg versus placebo, Outcome 8 Relief of associated symptoms at 2 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 1 Pain‐free at 2 h." data-id="CD008616-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 1 Pain‐free at 2 h.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 2 Headache relief at 2 h." data-id="CD008616-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 2 Headache relief at 2 h.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 3 Headache relief at 1 h." data-id="CD008616-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 3 Headache relief at 1 h.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 4 24‐h sustained pain‐free." data-id="CD008616-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 4 24‐h sustained pain‐free.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 5 24‐h sustained headache relief." data-id="CD008616-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 5 24‐h sustained headache relief.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 6 Any adverse event." data-id="CD008616-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 6 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 7 Specific adverse events." data-id="CD008616-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 7 Specific adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 8 Use of rescue medication ‐ subgroups." data-id="CD008616-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 8 Use of rescue medication ‐ subgroups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 9 Relief of associated symptoms at 2 h." data-id="CD008616-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 9 Relief of associated symptoms at 2 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 10 Free of functional disability at 2 h." data-id="CD008616-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Zolmitriptan 5 mg versus placebo, Outcome 10 Free of functional disability at 2 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zolmitriptan 10 mg versus placebo, Outcome 1 Pain‐free at 2 h." data-id="CD008616-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Zolmitriptan 10 mg versus placebo, Outcome 1 Pain‐free at 2 h.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zolmitriptan 10 mg versus placebo, Outcome 2 Headache relief at 2 h." data-id="CD008616-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Zolmitriptan 10 mg versus placebo, Outcome 2 Headache relief at 2 h.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zolmitriptan 10 mg versus placebo, Outcome 3 Any adverse event." data-id="CD008616-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Zolmitriptan 10 mg versus placebo, Outcome 3 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Zolmitriptan 10 mg versus placebo, Outcome 4 Specific adverse events." data-id="CD008616-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Zolmitriptan 10 mg versus placebo, Outcome 4 Specific adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Zolmiriptan 2.5 mg versus sumatriptan 50 mg, Outcome 1 Headache relief at 2 h." data-id="CD008616-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Zolmiriptan 2.5 mg versus sumatriptan 50 mg, Outcome 1 Headache relief at 2 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Zolmiriptan 2.5 mg versus sumatriptan 50 mg, Outcome 2 Any adverse event." data-id="CD008616-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Zolmiriptan 2.5 mg versus sumatriptan 50 mg, Outcome 2 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Zolmiriptan 2.5 mg versus sumatriptan 50 mg, Outcome 3 Withdrawals due to adverse events." data-id="CD008616-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Zolmiriptan 2.5 mg versus sumatriptan 50 mg, Outcome 3 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Zolmitripan 5 mg versus sumatriptan 50 mg, Outcome 1 Headache relief at 2 h." data-id="CD008616-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Zolmitripan 5 mg versus sumatriptan 50 mg, Outcome 1 Headache relief at 2 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Zolmitripan 5 mg versus sumatriptan 50 mg, Outcome 2 Any adverse event." data-id="CD008616-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Zolmitripan 5 mg versus sumatriptan 50 mg, Outcome 2 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008616-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/urn:x-wiley:14651858:media:CD008616:CD008616-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_t/tCD008616-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Zolmitripan 5 mg versus sumatriptan 50 mg, Outcome 3 Withdrawals due to adverse events." data-id="CD008616-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Zolmitripan 5 mg versus sumatriptan 50 mg, Outcome 3 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/media/CDSR/CD008616/image_n/nCD008616-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008616-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral zolmitriptan 2.5 mg compared with placebo for migraine headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with migraine headache ‐ moderate or severe pain</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: oral zolmitriptan 2.5 mg</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> comparator</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> intervention</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>NNT or NNTH and/or<br/> relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies, attacks, events</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain‐free response at 2 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 5.0 (4.5 to 5.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 studies, 5223 attacks, 1157 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 2 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>610 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 3.2 (3.0 to 3.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 studies, 4567 attacks, 2184 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 1 h</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 6.0 (5.2 to 7.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 studies, 4123 attacks, 1273 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained pain‐free during the 24 h post dose</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 7.7 (5.9 to 11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies, 984 attacks, 145 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> <p>Downgraded due to small number of studies and events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained headache relief during the 24 h post dose</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNT 4.1 (3.5 to 5.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 1457 attacks, 451 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower NNTs are better than higher NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least one AE</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH 7.0 (6.1 to 8.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 studies, 5717 attacks, 1464 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher NNHs are better than lower NNTs</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious AE*</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2.0 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.3 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>insufficient data to calculate</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,561 attacks, 30 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>*all doses &gt; 1 mg and all formulations combined</p> <p>Downgraded due to small number of events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AE:</b> adverse event;<b>CI:</b> Confidence interval; <b>NNT</b> : number needed to treat; <b>NNH</b>: number needed to harm </p> <p>Note: NNT or NNH is reported when an outcome is statistically different from placebo or comparator. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/full#CD008616-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008616-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Zolmitriptan 1 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [2.00, 3.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Headache relief at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.49, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.01, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Use of rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.58, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Relief of associated symptoms at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.04, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Photophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.09, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Phonophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.40, 3.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Zolmitriptan 1 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008616-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Zolmitriptan 2.5 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [2.64, 3.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Headache relief at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.91, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 24‐h sustained pain‐free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.51 [2.12, 5.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 24‐h sustained headache relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [2.37, 3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.57, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Specific adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.17, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.36, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Dizziness/vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.57, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Paresthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [1.55, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Vasodilation/warm feeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.18, 4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.26, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Tightness (not chest)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2919</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.56 [3.58, 31.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Heaviness (not chest)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.06 [1.15, 14.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.74, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Use of rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.51, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Relief of associated symptoms at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.37, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Photophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.78, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Phonophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.80, 2.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Zolmitriptan 2.5 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008616-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Zolmitriptan 5 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [2.68, 3.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oral tablet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [2.69, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Nasal spray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [2.51, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Headache relief at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.88, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oral tablet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.78, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Nasal spray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.91, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Headache relief at 1 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.64, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oral tablet ‐ standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.54, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Nasal spray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.61, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 24‐h sustained pain‐free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.65 [3.64, 5.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oral tablet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [2.20, 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Nasal spray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.94 [3.74, 6.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 24‐h sustained headache relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [2.87, 3.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Oral tablet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [2.02, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Nasal spray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.95 [3.42, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [2.02, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Oral tablet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.76, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Nasal spray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [2.13, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Specific adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [1.67, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.50, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Dizziness/vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.61, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Paresthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.81, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Vasodilation/warm feeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [1.65, 5.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Taste disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.48 [7.08, 12.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.41, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Tightness (not chest)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.06 [7.01, 75.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9 Heaviness (not chest)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.73 [2.01, 11.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.36, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Use of rescue medication ‐ subgroups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.52, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Oral tablet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.55, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Nasal spray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.50, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Relief of associated symptoms at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.36, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Photophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.81, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Phonophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.81, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Free of functional disability at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [2.11, 2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Zolmitriptan 5 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008616-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Zolmitriptan 10 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.79 [4.19, 14.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Headache relief at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [1.98, 3.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.83, 2.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Specific adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.27 [1.58, 6.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [1.71, 6.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Dizziness/vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [1.49, 4.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Paresthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.49 [2.99, 36.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Vasoldilation/warm feeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.01 [1.44, 11.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [1.20, 5.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Zolmitriptan 10 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008616-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Zolmiriptan 2.5 mg versus sumatriptan 50 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache relief at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.90, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.99, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.52, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Zolmiriptan 2.5 mg versus sumatriptan 50 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008616-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Zolmitripan 5 mg versus sumatriptan 50 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache relief at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.96, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.71, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Zolmitripan 5 mg versus sumatriptan 50 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008616.pub2/references#CD008616-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008616.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008616-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008616-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008616-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD008616-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008616-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008616\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008616\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008616\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008616\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008616\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008616.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008616.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008616.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008616.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008616.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715517732"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008616.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715517736"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008616.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d89076f689374',t:'MTc0MDcxNTUxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 